omeprazole has been researched along with Recrudescence in 399 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole, bismuth subcitrate, furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success." | 9.13 | Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. ( Barbuti, RC; Eisig, JN; Felga, GE; Navarro-Rodriguez, T; Silva, FM; Zaterka, S, 2008) |
| "Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo." | 9.11 | Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005) |
| "A total of 101 patients who had peptic ulcer bleeding based on endoscopic findings of nonbleeding visible vessels or fresh adherent clots were randomly assigned to receive omeprazole (40 mg p." | 9.10 | Comparison of oral omeprazole and endoscopic ethanol injection therapy for prevention of recurrent bleeding from peptic ulcers with nonbleeding visible vessels or fresh adherent clots. ( Jung, HK; Jung, SA; Kim, DY; Lee, HC; Moon, IH; Son, HY; Yi, SY; Yoo, K, 2002) |
| "To compare the safety and efficacy of pantoprazole with ranitidine for the maintenance of endoscopically documented healed (grade 0 or 1) erosive oesophagitis." | 9.10 | Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. ( Bochenek, WJ; Metz, DC, 2003) |
| "To compare the efficacy and safety of two doses of rabeprazole with 20 mg omeprazole in the maintenance treatment of erosive gastro-oesophageal reflux disease over 5 years." | 9.10 | A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. ( Bardhan, KD; Fiocca, R; Humphries, TJ; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2003) |
| "To compare the efficacy of a "Helicobacter pylori test and treat" strategy with that of an empirical trial of omeprazole in the non-endoscopic management by empirical prescribing of young patients with dyspepsia." | 9.10 | Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. ( Balzano, A; de Nucci, C; Manes, G; Menchise, A, 2003) |
| " Both pantoprazole and placebo resulted in a marked improvement in laryngitis scores (decrease of 8." | 9.10 | Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. ( Eherer, AJ; Friedrich, G; Habermann, W; Hammer, HF; Kiesler, K; Krejs, GJ, 2003) |
| "Duodenal ulcer cure, as a systemic gastroenterologic disease, can be achieved in some patients by the addition of the nootropic drug piracetam to current antisecretory and antihelicobacter therapy." | 9.10 | [Piracetam in combined pathogenetic therapy of recurrent duodenal ulcer]. ( Shchetkin, DI; Tsimmerman, IaS, 2002) |
| "To investigate the eradication rate of Helicobacter pylori with omeprazole, amoxicillin and clarithromycin during 6 days in patients with duodenal ulcer." | 9.09 | [Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer]. ( Barrachina, M; Bixquert, M; Cuquerella, J; del Val, A; García-Romero, E; Garrigues, V; Higón, MD; Ponce, J; Pons, V, 1999) |
| "To study the efficacy of omeprazole triple therapy in the eradication of Helicobacter pylori in patients with active gastric ulcer, and to assess healing and relapse of gastric ulcer." | 9.09 | The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. ( Bayerdörffer, E; Diete, U; Gil, J; Lind, T; Malfertheiner, P; Misiuna, P; O'Morain, C; Sipponen, P; Spiller, RC; Stasiewicz, J; Treichel, H; Ujszászy, L; Unge, P; Zanten, SJ; Zeijlon, L, 1999) |
| "To compare lansoprazole 30 mg once daily, lansoprazole 15 mg once daily and ranitidine 150 mg once nightly in the prevention of duodenal ulcer relapse in patients whose duodenal ulcers had been previously healed with lansoprazole 30 mg once daily or ranitidine 300 mg nightly." | 9.09 | Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. ( Bardhan, KD; Crouch, SL; Crowe, J; Keeling, PN; Thompson, RP; Trewby, PN; Weir, D, 1999) |
| "Lansoprazole safely and effectively reduces duodenal ulcer recurrence and ulcer-related symptoms." | 9.09 | Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1999) |
| "We evaluated the effectiveness and safety profile of 10 and 20 mg of rabeprazole, a new proton pump inhibitor, once daily versus placebo in preventing endoscopic and symptomatic relapse for up to 1 yr among patients with healed erosive or ulcerative gastroesophageal reflux disease (GERD)." | 9.09 | Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. ( Barth, J; Caos, A; Dayal, Y; Moskovitz, M; Niecestro, R; Perdomo, C, 2000) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 9.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| "This study attempted to determine the efficacy of lansoprazole plus clarithromycin therapy in the eradication of Helicobacter pylori in gastric ulcer patients." | 9.08 | Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. ( Aisawa, T; Akagi, T; Fukuda, S; Fukushi, M; Mizuki, I; Munakata, A; Ohkawa, K; Sakata, Y; Shimoyama, T; Yoshida, Y, 1995) |
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 9.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| "In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated." | 9.08 | The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995) |
| "The aim of this study was to establish if the discontinuous assumption of omeprazole was effective to reduce the recurrence of duodenal ulcer disease as the cyclic periodical assumptions of the same drug." | 9.08 | [Long-term cyclic and periodic omeprazole in the prevention of recurrences of duodenal ulcer]. ( Bisi, G; Cappellari, L; Caravita, L; Dalla Libera, M; Gullini, S; Massari, M; Matarese, V; Tartari, V; Zibordi, U, 1995) |
| "A multicenter, double-blind study was conducted in 268 patients to compare the safety and efficacy of 15, 30, and 60 mg of lansoprazole and placebo in the treatment of gastric ulcer." | 9.08 | Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer. ( Avner, DL; Berry, W; Erfling, W; McFarland, M; Movva, R; Nelson, KJ, 1995) |
| "We performed an open, prospective, randomized, three-cell, 6-month clinical trial on the prevention of duodenal ulcer (DU) relapse, comparing three omeprazole schedules, i." | 9.08 | Six months of omeprazole 20 mg daily, 20 mg every other day or 40 mg at weekends in duodenal ulcer patients: a multicenter, prospective, comparative study. Interdisciplinary Group for Ulcer Study. ( , 1995) |
| " The aim of this controlled, randomized, prospective study was to compare the effect of these two regimens and a further regimen for metronidazole-resistant patients on duodenal ulcer healing, H." | 9.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| "To establish the efficacy of omeprazole combined with two antibiotics for Helicobacter pylori eradication and duodenal ulcer relapse." | 9.08 | Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M; Maconi, G; Minguzzi, M, 1995) |
| " pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131)." | 9.08 | Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. ( Bayerdörffer, E; Heldwein, W; Höchter, W; Klann, H; Mannes, GA; Miehlke, S; Schmitt, W; Simon, T; Sommer, A; Weingart, J, 1995) |
| "The proton-pump inhibitor, lansoprazole, a more potent gastric acid inhibitor with a longer action than H2-receptor antagonists, should heal refractory gastric ulcers more effectively." | 9.08 | A trial of lansoprazole in refractory gastric ulcer. ( Girdwood, AH; Louw, JA; Marks, IN; Simjee, AE; van Rensburg, CJ, 1996) |
| "To determine the efficacy of lansoprazole 30 mg given in the morning compared with high-dose ranitidine 300 mg twice daily in the treatment of patients with oesophageal strictures." | 9.08 | Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. ( Christian, J; Foster, CS; Garrett, AD; Gough, AL; Langworthy, CH; Swarbrick, ET, 1996) |
| "To investigate differences between omeprazole and Helicobacter pylori eradication in patients with duodenal ulcers refractory to H2-receptor antagonists and to compare the recurrence rates after the two treatments." | 9.08 | Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication. ( Avsar, E; Gültekin, O; Kalayci, C; Kiziltas, S; Lawrence, R; Tözün, N; Ulusoy, NB, 1996) |
| "To determine the effect of Helicobacter pylori eradication with omeprazole and amoxycillin, with or without metronidazole, on the 12-month course of duodenal ulcer disease." | 9.08 | Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole. ( Axon, AT; Bate, CM; Bell, GD; Martin, JL; Richardson, PD; Taylor, MD; Tildesley, G, 1996) |
| " pylori from the gastric mucosa, and omeprazole frequently is used for the treatment of duodenal ulcer disease, prompting the interest to investigate rigorously the combination of clarithromycin and omeprazole for eradicating H." | 9.08 | Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. ( Dettmer, A; Fraser, AG; O'Morain, C; Rambow, A; von Fritsch, E, 1996) |
| "The use of omeprazole is more effective than cimetidine in increasing intragastric pH and reducing rebleeding episodes in patients with bleeding peptic ulcers after successful endoscopic therapy." | 9.08 | A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. ( Lee, FY; Lin, HJ; Lo, WC; Perng, CL; Tseng, GY, 1998) |
| " The aim of the present study was to assess efficacy and tolerability of the proton pump inhibitors lansoprazole given at bedtime as compared to ranitidine, both in acute and maintenance treatment of duodenal ulcer." | 9.08 | Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial. ( Dattilo, M; Russo, A, 1997) |
| "In this randomized multicentre study, 267 duodenal ulcer patients were treated for 2 weeks with omeprazole 40 bid (Group A) or 20 mg bid (Group B), respectively, and with amoxycillin 0." | 9.08 | Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study. ( Annibale, B; Bordi, C; Cesana, B; Damilano, I; Franceschi, M; Maconi, G; Pilato, FP, 1997) |
| "Our purpose was to compare the safety and efficacy of lansoprazole 15 mg and 30 mg with placebo in preventing recurrence in 49 patients with a history of gastric ulcer." | 9.08 | Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1998) |
| "After healing and symptom relief had been obtained on open therapy with lansoprazole 30 mg daily, 103 patients with reflux oesophagitis grade 1 or 2 were randomized to maintenance therapy with lansoprazole 15 or 30 mg daily, and time until recurrence of symptoms and/or endoscopic changes was recorded." | 9.08 | Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. ( Berstad, A; Hatlebakk, JG, 1997) |
| "To investigate the efficacy of daily maintenance treatment with omeprazole 10 mg in reducing the relapse rate of healed erosive oesophagitis." | 9.08 | Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo. ( Bardhan, KD; Bishop, A; Brooks, A; Cherian, P; D'Silva, J; Gillon, KR; Jones, RB; Morris, P; Patterson, J; Polak, J; Thompson, M; Vaishnavi, A; Wason, C, 1998) |
| "We investigated the relationship between histological maturity of healed duodenal ulcer and ulcer recurrence after treatment with omeprazole or cimetidine for 4 weeks." | 9.07 | Histological maturity of healed duodenal ulcer and ulcer recurrence after treatment with omeprazole or cimetidine. ( Chen, SH; Liao, CH; Lien, GS; Pan, S, 1994) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 9.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| "Duodenal ulcer relapse rates after therapy with sucralfate or bismuth are lower than those after H2-receptor antagonist therapy." | 9.07 | Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates. ( Jaskiewicz, K; Lastovica, A; Le Roux, E; Louw, JA; Lucke, W; Marks, IN; Winter, T; Zak, J, 1992) |
| " In this 2:1 randomized, double-blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out-patients suffering from uncomplicated duodenal ulcer." | 9.07 | Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. ( Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA, 1992) |
| "The present study determined whether the rate of relapse of duodenal ulcer was reduced after ulcer healing with omeprazole compared with ranitidine or placebo." | 9.07 | Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: a double-blind, multicenter, 6-month study. The Omeprazole Duodenal Ulcer Study Group. ( Cagliola, AJ; Colon-Pagan, J; Graham, DY; Johnson, TL; Marks, JW; McCullough, AJ; Morse, RS; Sklar, M; Stone, RC; Walsh, JH, 1992) |
| "Acid secretory responses and parietal cell sensitivity (PCS) have been studied in 21 duodenal ulcer patients before and after successful treatment with omeprazole (n = 7), sucralfate (n = 7), or Maalox (n = 7)." | 9.07 | Acid secretory responses and parietal cell sensitivity following duodenal ulcer healing with omeprazole, sucralfate, and Maalox. ( Bridger, S; Johnston, DA; Marks, IN; Tigler-Wybrandi, NA; Young, GO; Zak, J, 1991) |
| "Forty-four patients with esophagitis refractory to standard H2-blocker therapy, who had healed after a 4- to 16-wk course with either 20-40 mg omeprazole or ranitidine at doses of 300-600 mg daily in a randomized double-blind study, commenced a 3-month maintenance course of therapy with 40 mg bid famotidine." | 9.07 | High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study. ( Bianchi-Porro, G; Bonavina, L; Pace, F; Peracchia, A; Sangaletti, O; Termini, R; Vigneri, S, 1991) |
| "In a double-blind, parallel-group clinical trial of 195 patients with duodenal ulcers who after a short-term study had relief of pain and healed ulcers proved endoscopically, 65 were randomized to receive 20 mg omeprazole 3 days a week (once in the morning from Friday to Sunday), 64 to receive 10 mg omeprazole once daily in the morning, and 66 to receive placebo for up to 6 months." | 9.07 | Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial. ( Andersen, BN; Eriksen, J; Hansen, J; Havelund, T; Kjaergaard, J; Lauritsen, K; Laursen, LS; Rask-Madsen, J; Rehfeld, JF, 1991) |
| "In a Swedish-Norwegian multicentre study patients with endoscopically verified duodenal ulcers (greater than 5 mm) were randomized to 2 or 4 weeks of treatment with either 20 mg omeprazole once daily or 300 mg ranitidine once daily." | 9.07 | Two and four weeks' treatment for duodenal ulcer. Symptom relief and clinical remission comparing omeprazole and ranitidine. Scandinavian Clinics for United Research. ( Carling, L; Engström, G; Glise, H; Hallerbäck, B; Martinson, J; Solhaug, JH; Unge, P, 1991) |
| "To investigate the efficacy of standard and low dosage of omeprazole in the healing of duodenal ulcer, 270 patients with endoscopically active duodenal ulcer were randomized to receive omeprazole, 10 mg or 20 mg every morning, or ranitidine, 150 mg twice daily, using the double-dummy technique." | 9.06 | Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: a randomized double-blind study with weekly endoscopic assessment. ( Branicki, FJ; Hui, WM; Lai, CL; Lam, SK; Lau, WY; Lok, AS; Ng, MM; Poon, GP, 1989) |
| "Two hundred and seventeen gastric ulcer patients whose ulcers had healed during omeprazole (30 mg) or cimetidine (1 g) treatment entered a follow-up study for 6 months." | 9.06 | Relapse of gastric ulcers after healing with omeprazole and cimetidine. A double-blind follow-up study. Danish Omeprazole Study Group. ( , 1989) |
| "One hundred and twenty-nine patients were studied with regard to healing of duodenal ulcers with 30 mg omeprazole once daily, recurrence rates after 2 and 4 weeks' treatment in patients with ulcers healed after 2 weeks, and recurrences in rapid and slow healers." | 9.06 | Duodenal ulcer treated with omeprazole: healing and relapse rates. Does treatment duration influence subsequent remission? ( Andersen, OK; Bernklev, T; Farup, PG; Halvorsen, L; Rosseland, AR, 1989) |
| "In a preliminary study to compare the effects of different doses of omeprazole 44 patients with endoscopically diagnosed duodenal ulceration randomly received omeprazole 20 mg, 30 mg, 40 mg, or 60 mg daily for four weeks." | 9.05 | Omeprazole in duodenal ulceration: acid inhibition, symptom relief, endoscopic healing, and recurrence. Cooperative study. ( , 1984) |
| "We conducted a double-blind randomized study of 132 patients to determine whether the new, investigational proton-pump inhibitor, omeprazole (30 mg per day), would accelerate healing and pain relief, as compared with cimetidine (1 g per day), in patients with duodenal ulcer." | 9.05 | Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. ( Andersen, HH; Bendtsen, F; Bytzer, P; Højlund, M; Jensen, KG; Kelbaek, H; Lauritsen, K; Linde, J; Rask-Madsen, J; Rune, SJ, 1985) |
| "A 53-year old female patient with duodenal ulcer and Helicobacter pylori infection was treated three times with a proton pump inhibitor-based triple therapy, such as lansoprazole-clarithromycin-amoxicillin (INN, amoxicilline) and lansoprazole-minocycline-cefaclor." | 8.80 | Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. ( Furuta, T; Hanai, H; Ishizaki, T; Ohashi, K; Shirai, N; Takashima, M; Xiao, F, 2000) |
| "Individual data from 1154 patients included in five independently conducted, randomized, long-term clinical trials of the efficacy of different dosage regimens of omeprazole, standard ranitidine treatment and placebo for the prevention of relapse of oesophagitis were pooled for this meta-analysis." | 8.79 | Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. ( Carlsson, R; Dent, J; Frison, L; Galmiche, JP; Lundell, L, 1997) |
| "To evaluate the effect of drug interaction between omeprazol and clopidogrel in hospital readmission of patients with acute coronary syndrome (ACS)." | 7.80 | [Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study]. ( Amariles, P; Angulo, NY; Betancourth, PM; Ceballos, M; Holguín, H, 2014) |
| "To evaluate the omeprazole maintenance therapy in patients with recurrent ulcer bleeding after surgery for duodenal ulcer." | 7.73 | Omeprazole maintenance therapy prevents recurrent ulcer bleeding after surgery for duodenal ulcer. ( Demertzis, K; Emmanuel, T; Ladas, SD; Polymeros, D; Tassios, P; Triantafyllou, K, 2006) |
| "The efficacy of a paste formulation of the H+, K+, -ATPase inhibitor omeprazole was evaluated in standardbred racehorses for the treatment and prevention of gastric ulcers." | 7.72 | Efficacy of a paste formulation of omeprazole for the treatment of naturally occurring gastric ulcers in training standardbred racehorses in Canada. ( Alva, R; Dionne, R; Doucet, MY; Ericsson, G; Vrins, AA, 2003) |
| "A 3-month observational study was conducted in an OTC setting to determine whether consumers could (1) correctly self-select to use omeprazole for frequent heartburn, (2) comply with a product label that calls for 14 consecutive days of once-daily dosing, and (3) use more than 14 doses of medication only under the advice of a physician." | 7.72 | Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. ( Allgood, G; Allgood, L; Fendrick, AM; Grender, J; Peura, D; Schachtel, B; Shaw, M, 2004) |
| "Six captive cheetahs (Acinonyx jubatus) with severe gastritis diagnosed by gastric endoscopy and mucosal histopathology were treated with omeprazole, metronidazole, and amoxicillin for 3 wk." | 7.72 | Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis. ( Burroughs, R; Lane, E; Lobetti, R, 2004) |
| "Omeprazole is an effective long-term drug for gastroesophageal reflux disease after failed fundoplication in children." | 7.71 | Omeprazole maintenance therapy for gastroesophageal reflux disease after failure of fundoplication. ( Blair, GK; Israel, DM; Pashankar, D, 2001) |
| "The efficacy of omeprazole 20 mg a day was assessed against ranitidine 150 mg twice a day in the healing and relapse of duodenal ulcer." | 7.69 | Healing and relapse rates of duodenal ulcer with omeprazole vs ranitidine. ( Ahmed, W; Alam, SE; Qureshi, H; Zuberi, SJ, 1995) |
| "We retrospectively investigated the efficacy of high dose omeprazole compared to a combined therapy of famotidine, pirenzepine and antacid for acute upper gastrointestinal hemorrhage (AUGIH) also adjuvant to endoscopic injection therapy if indicated." | 7.69 | [High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison]. ( Busam, J; Garbe, WE, 1994) |
| "Empiric omeprazole therapy is a reasonable, initial approach to patients with suspected gastroesophageal reflux-related posterior laryngitis." | 7.69 | Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. ( Delgaudio, JM; Grist, WJ; Gussack, G; Waring, JP; Wo, JM, 1997) |
| "The aim of this study is to propose a regimen of omeprazole 20 mg twice weekly for the prevention of duodenal ulcer (DU) relapse." | 7.68 | [Study on omeprazole 20 mg twice weekly in prevention of duodenal ulcer relapse]. ( Bei, L; Chen, SP; Wen, SH, 1993) |
| " Dosing was adjusted by monitoring intragastric pH, and esophagoscopy was repeated after 8-12 weeks of omeprazole treatment." | 6.69 | Histological esophagitis: clinical and histological response to omeprazole in children. ( Calenda, KA; Dayal, Y; Mobassaleh, M; Strauss, RS, 1999) |
| " HP was eradicated by combined treatment with high-dose omeprazole (2 x 40 mg) and amoxicillin (2 x 1,000 mg; n = 27) administered for 10 days (OME + AMX); alternatively, patients were treated with omeprazole monotherapy (OME) using the same dosage (n = 25)." | 6.68 | Two-year follow-up of duodenal ulcer patients treated with omeprazole and amoxicillin. ( Bayerdörffer, E; Dirschedl, P; Hatz, R; Höchter, W; Lehn, N; Mannes, GA; Miehlke, S; Ruckdeschel, G; Sommer, A; Weingart, J, 1995) |
| "Gastro-oesophageal reflux disease (GORD) is a frequent cause for consultation in general practice and is a chronically relapsing disease." | 6.68 | Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. ( Copeman, MB; Hole, J; Newland, RD; Patel, AC; Turbitt, ML; Venables, TL, 1997) |
| "For H." | 6.68 | Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. ( Bardhan, KD; Graham, DY; Hunt, RH; O'Morain, CA, 1997) |
| "Time to ulcer recurrence was significantly longer (P < 0." | 6.68 | Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Jhala, N; Lanza, F; Silvers, D; Winters, J, 1997) |
| "Lansoprazole has a wide margin of safety and is well tolerated when administered as monotherapy in short- and long-term clinical trials." | 6.41 | Lansoprazole for maintenance of remission of erosive oesophagitis. ( Ballard, ED; Freston, JW; Huang, B; Jackson, RL, 2002) |
| "The therapeutic approach to gastroesophageal reflux disease (GERD) in intellectually disabled individuals has not been studied extensively." | 5.30 | Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy. ( Bohmer, CJ; Devillé, WL; Klinkenberg-Knol, EC; Meuwissen, SG; Niezen-de Boer, MC; Tuynman, HA; Voskuil, JH, 1997) |
| "When omeprazole was re-started she developed fever and acute renal failure, which again settled quickly on discontinuation of omeprazole." | 5.30 | Pyrexia, anaemia and acute renal failure secondary to omeprazole. ( Arnold, IR; Ferner, RE; Landray, MJ; Ringrose, T, 1998) |
| "Duodenal ulcer is a chronic disease with a high risk of relapse--if left untreated, the relapse rate is 50-80% per year (1)." | 5.29 | Prevention of duodenal ulcer relapse by long-term treatment with omeprazole. ( Festen, HP, 1994) |
| " From these data, we conclude that personalized maintenance therapy with omeprazole is the most cost-effective: a dosage of 20 mg/day is extremely effective in maintaining remission, and is therefore most indicated in patients at risk; omeprazole 20 mg/day every-other-day affords better compliance, lower costs and fewer relapses with respect to standard H2-antagonist dosages." | 5.29 | [Evaluation of the cost of maintenance therapy (6 months) with 150 mg ranitidine vs 20 mg omeprazole vs 20 mg omeprazole every other day in duodenal ulcer]. ( Battaglia, G; Chiozzini, G; De Bona, M; De Boni, M; Di Mario, F; Grasso, GA; Pasquino, M; Saggioro, A; Vianello, F, 1993) |
| "Adopting randomized and controlled principle, the 46 patients with active peptic ulcer were randomly allocated into the treated group and the control group, they received respectively the treatment of YHF + Omeprazole and Omeprazole alone for 5 weeks." | 5.14 | [Effect of yiqi huoxue formula on healing quality and recurrence rate of peptic ulcer]. ( Ge, HN; Guo, JW; Zhang, WP, 2009) |
| "To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole, bismuth subcitrate, furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success." | 5.13 | Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. ( Barbuti, RC; Eisig, JN; Felga, GE; Navarro-Rodriguez, T; Silva, FM; Zaterka, S, 2008) |
| " After appropriate assessment with esophageal manometry and 24 h ambulatory pHmetry, patients with documented gastroesophageal reflux disease (GERD) were treated with omeprazole continuously." | 5.12 | Single-session, graded esophageal dilation without fluoroscopy in outpatients with lower esophageal (Schatzki's) rings: a prospective, long-term follow-up study. ( Bergele, C; Mantides, A; Sgouros, SN; Stefanidis, G; Vassiliadis, K; Vlachogiannakos, J, 2007) |
| "248 patients with Hp-associated active duodenal ulcer confirmed by endoscopy, 193 males and 55 females, were randomized to receive OAC(250): omeprazole (0." | 5.11 | [Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study]. ( , 2004) |
| "The main purpose of this study was to compare omeprazole (ome) plus two antibiotics (OMC) with omeprazole plus placebo (OP) with regard to gastric ulcer relapse for a period of 2 years in patients who were Helicobacter pylori-positive at inclusion." | 5.11 | Long-term effects of eradication of Helicobacter pylori on relapse and histology in gastric ulcer patients: a two-year follow-up study. ( Backman, M; Befrits, R; Hedenborg, L; Leijonmarck, CE; Sjöstedt, S; Tour, R, 2004) |
| "Heartburn-dominant uninvestigated dyspepsia patients from 46 primary care centres were randomized to one of two active treatment strategies: omeprazole 20 mg daily (proton pump inhibitor-start) or ranitidine 150 mg bid (H2-receptor antagonist-start) for the first 4-8 weeks, stepping up to omeprazole 40 or 20 mg daily, respectively, for 4-8 weeks for persistent symptoms." | 5.11 | Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study. ( Armstrong, D; Barkun, AN; Chakraborty, B; Chiba, N; Sinclair, P; Smyth, S; Thomson, AB; Veldhuyzen van Zanten, SJ; White, RJ, 2005) |
| "Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment." | 5.11 | Management of symptoms in step-down therapy of gastroesophageal reflux disease. ( Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y, 2005) |
| "Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo." | 5.11 | Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005) |
| "Celecoxib was as effective as lansoprazole co-therapy in the prevention of recurrences of ulcer complications in subjects with a history of NSAID-related complicated peptic ulcers." | 5.11 | Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005) |
| "A total of 101 patients who had peptic ulcer bleeding based on endoscopic findings of nonbleeding visible vessels or fresh adherent clots were randomly assigned to receive omeprazole (40 mg p." | 5.10 | Comparison of oral omeprazole and endoscopic ethanol injection therapy for prevention of recurrent bleeding from peptic ulcers with nonbleeding visible vessels or fresh adherent clots. ( Jung, HK; Jung, SA; Kim, DY; Lee, HC; Moon, IH; Son, HY; Yi, SY; Yoo, K, 2002) |
| "To compare the safety and efficacy of pantoprazole with ranitidine for the maintenance of endoscopically documented healed (grade 0 or 1) erosive oesophagitis." | 5.10 | Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. ( Bochenek, WJ; Metz, DC, 2003) |
| "To compare the efficacy and safety of two doses of rabeprazole with 20 mg omeprazole in the maintenance treatment of erosive gastro-oesophageal reflux disease over 5 years." | 5.10 | A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. ( Bardhan, KD; Fiocca, R; Humphries, TJ; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2003) |
| "To compare the efficacy of a "Helicobacter pylori test and treat" strategy with that of an empirical trial of omeprazole in the non-endoscopic management by empirical prescribing of young patients with dyspepsia." | 5.10 | Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. ( Balzano, A; de Nucci, C; Manes, G; Menchise, A, 2003) |
| " Both pantoprazole and placebo resulted in a marked improvement in laryngitis scores (decrease of 8." | 5.10 | Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. ( Eherer, AJ; Friedrich, G; Habermann, W; Hammer, HF; Kiesler, K; Krejs, GJ, 2003) |
| "Data were pooled on patients (n = 826) with a diagnosis of functional dyspepsia from two placebo-controlled trials who were treated with omeprazole, 10 or 20 mg once daily, for 4 weeks." | 5.10 | Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? ( Bolling-Sternevald, E; Glise, H; Junghard, O; Lauritsen, K; Talley, NJ, 2003) |
| "Duodenal ulcer cure, as a systemic gastroenterologic disease, can be achieved in some patients by the addition of the nootropic drug piracetam to current antisecretory and antihelicobacter therapy." | 5.10 | [Piracetam in combined pathogenetic therapy of recurrent duodenal ulcer]. ( Shchetkin, DI; Tsimmerman, IaS, 2002) |
| "To investigate the eradication rate of Helicobacter pylori with omeprazole, amoxicillin and clarithromycin during 6 days in patients with duodenal ulcer." | 5.09 | [Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer]. ( Barrachina, M; Bixquert, M; Cuquerella, J; del Val, A; García-Romero, E; Garrigues, V; Higón, MD; Ponce, J; Pons, V, 1999) |
| "To study the efficacy of omeprazole triple therapy in the eradication of Helicobacter pylori in patients with active gastric ulcer, and to assess healing and relapse of gastric ulcer." | 5.09 | The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. ( Bayerdörffer, E; Diete, U; Gil, J; Lind, T; Malfertheiner, P; Misiuna, P; O'Morain, C; Sipponen, P; Spiller, RC; Stasiewicz, J; Treichel, H; Ujszászy, L; Unge, P; Zanten, SJ; Zeijlon, L, 1999) |
| "To compare lansoprazole 30 mg once daily, lansoprazole 15 mg once daily and ranitidine 150 mg once nightly in the prevention of duodenal ulcer relapse in patients whose duodenal ulcers had been previously healed with lansoprazole 30 mg once daily or ranitidine 300 mg nightly." | 5.09 | Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. ( Bardhan, KD; Crouch, SL; Crowe, J; Keeling, PN; Thompson, RP; Trewby, PN; Weir, D, 1999) |
| "Lansoprazole safely and effectively reduces duodenal ulcer recurrence and ulcer-related symptoms." | 5.09 | Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1999) |
| "Patients with functional dyspepsia from Denmark, France, Germany, The Netherlands, Hungary, and Poland (n = 567 (215 men), 18-80 years old) were followed up for 3 months after a 4-week treatment trial with omeprazole (20 mg or 10 mg) or placebo." | 5.09 | Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study. ( Bolling-Sternevald, E; Kordecki, H; Meineche-Schmidt, V; Ohlsson, L; Pap, A; Schmid, V; Talley, NJ; Wahlqvist, P; Wiklund, I, 1999) |
| "After a complete diagnostic workup, 792 patients with functional dyspepsia unresponsive to one week of low dose antacid treatment were randomised to two weeks of treatment with placebo, ranitidine 150 mg, omeprazole 10 mg, or omeprazole 20 mg daily." | 5.09 | Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. ( Arnold, R; Blum, AL; Fischer, M; Koelz, HR; Stolte, M, 2000) |
| " Patients with gastric ulcer (GU) or duodenal ulcer (DU) were enrolled in this study; 583 eligible patients (GU, 325; DU, 258) were administered lansoprazole (30 mg/day for 8 weeks for GU, and the same dosage for 6 weeks for DU) as first-line therapy, and a half dose of H2RA as maintenance therapy for 12 months." | 5.09 | Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor. ( Asaka, M; Asaki, S; Ashida, K; Harasawa, S; Hoshihara, Y; Kajiyama, G; Kaneko, E; Kobayashi, K; Muto, Y; Nakamura, T; Nakazawa, S; Ogawa, N; Sakaki, N; Takemoto, T; Yao, T, 2000) |
| "We evaluated the effectiveness and safety profile of 10 and 20 mg of rabeprazole, a new proton pump inhibitor, once daily versus placebo in preventing endoscopic and symptomatic relapse for up to 1 yr among patients with healed erosive or ulcerative gastroesophageal reflux disease (GERD)." | 5.09 | Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. ( Barth, J; Caos, A; Dayal, Y; Moskovitz, M; Niecestro, R; Perdomo, C, 2000) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 5.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| "This study attempted to determine the efficacy of lansoprazole plus clarithromycin therapy in the eradication of Helicobacter pylori in gastric ulcer patients." | 5.08 | Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. ( Aisawa, T; Akagi, T; Fukuda, S; Fukushi, M; Mizuki, I; Munakata, A; Ohkawa, K; Sakata, Y; Shimoyama, T; Yoshida, Y, 1995) |
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 5.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| "In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated." | 5.08 | The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995) |
| "The aim of this study was to establish if the discontinuous assumption of omeprazole was effective to reduce the recurrence of duodenal ulcer disease as the cyclic periodical assumptions of the same drug." | 5.08 | [Long-term cyclic and periodic omeprazole in the prevention of recurrences of duodenal ulcer]. ( Bisi, G; Cappellari, L; Caravita, L; Dalla Libera, M; Gullini, S; Massari, M; Matarese, V; Tartari, V; Zibordi, U, 1995) |
| "A multicenter, double-blind study was conducted in 268 patients to compare the safety and efficacy of 15, 30, and 60 mg of lansoprazole and placebo in the treatment of gastric ulcer." | 5.08 | Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer. ( Avner, DL; Berry, W; Erfling, W; McFarland, M; Movva, R; Nelson, KJ, 1995) |
| "We performed an open, prospective, randomized, three-cell, 6-month clinical trial on the prevention of duodenal ulcer (DU) relapse, comparing three omeprazole schedules, i." | 5.08 | Six months of omeprazole 20 mg daily, 20 mg every other day or 40 mg at weekends in duodenal ulcer patients: a multicenter, prospective, comparative study. Interdisciplinary Group for Ulcer Study. ( , 1995) |
| " The aim of this controlled, randomized, prospective study was to compare the effect of these two regimens and a further regimen for metronidazole-resistant patients on duodenal ulcer healing, H." | 5.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| "To evaluate whether eradication with omeprazole and amoxicillin results in a reduction of ulcer recurrence and rebleeding in patients with Helicobacter pylori-associated duodenal ulcer hemorrhage, patients with upper gastrointestinal hemorrhage from duodenal ulcers with stigmata of recent hemorrhage, a drop in hemoglobin level of more than 2 g/dL, and documented H." | 5.08 | Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. ( Brennenstuhl, M; Hammar, CH; Jaspersen, D; Koerner, T; Raschka, C; Schorr, W, 1995) |
| "To establish the efficacy of omeprazole combined with two antibiotics for Helicobacter pylori eradication and duodenal ulcer relapse." | 5.08 | Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M; Maconi, G; Minguzzi, M, 1995) |
| " pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131)." | 5.08 | Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. ( Bayerdörffer, E; Heldwein, W; Höchter, W; Klann, H; Mannes, GA; Miehlke, S; Schmitt, W; Simon, T; Sommer, A; Weingart, J, 1995) |
| " pylori infection and gastric ulcers unrelated to the use of nonsteroidal antiinflammatory drugs, one week of antibacterial therapy without acid suppression heals the ulcers as well as omeprazole and reduces the rate of their recurrence." | 5.08 | Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. ( Cheng, AF; Chung, SC; Leung, VK; Li, AK; Li, MK; Ling, TK; Ng, EK; Sung, JJ; Yung, MY, 1995) |
| ") in eradicating Helicobacter pylori in patients with duodenal ulcer successfully healed with omeprazole or ranitidine; second, to examine the influence of the eradication on duodenal ulcer recurrence rate after 12 months." | 5.08 | Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. A 12-month follow-up. ( Archimandritis, A; Balatsos, V; Delis, V; Kastanas, K; Mentis, A; Scandalis, N, 1995) |
| "The combined therapy with amoxycillin, metronidazole, and omeprazole is highly effective in both HP eradication and prevention of duodenal ulcer recurrence." | 5.08 | Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence. ( Alvisi, C; Bargiggia, S; Bianchi Porro, G; Cesana, B; Fiocca, R; Franceschi, M; Lazzaroni, M; Luinetti, O; Maconi, G; Perego, M; Solcia, E; Trespi, E; Villani, L, 1996) |
| "Changes in Helicobacter pylori-associated gastritis of the antrum and corpus were investigated in a large number of patients treated with omeprazole, with or without the addition of amoxycillin." | 5.08 | Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics. ( Carlsson, J; Fiocca, R; Rudbäck, A; Solcia, E; Villani, L; Zeijlon, L, 1996) |
| "During a period of 1 year 152 patients with gastric ulcers were randomly assigned to one of two treatment regimens: omeprazole 20 mg daily in the morning for 8 weeks (74 patients), or bismuth subsalicylate 600 mg three times daily for 8 weeks combined with 500 mg amoxicillin twice daily and 1000 mg tinidazole twice daily for the first 10 days (triple therapy) (78 patients)." | 5.08 | Cure of gastric ulcer disease after cure of Helicobacter pylori infection--German Gastric Ulcer Study. ( Bästlein, E; Bayerdörffer, E; Bolle, KH; Hatz, R; Heldwein, W; Höchter, W; Klann, H; Lehn, N; Mannes, GA; Meining, A; Miehlke, S; Ruckdeschel, G; Simon, T; Sommer, A; Stolte, M; Weingart, J, 1996) |
| "The proton-pump inhibitor, lansoprazole, a more potent gastric acid inhibitor with a longer action than H2-receptor antagonists, should heal refractory gastric ulcers more effectively." | 5.08 | A trial of lansoprazole in refractory gastric ulcer. ( Girdwood, AH; Louw, JA; Marks, IN; Simjee, AE; van Rensburg, CJ, 1996) |
| "To determine the efficacy of lansoprazole 30 mg given in the morning compared with high-dose ranitidine 300 mg twice daily in the treatment of patients with oesophageal strictures." | 5.08 | Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. ( Christian, J; Foster, CS; Garrett, AD; Gough, AL; Langworthy, CH; Swarbrick, ET, 1996) |
| "To investigate differences between omeprazole and Helicobacter pylori eradication in patients with duodenal ulcers refractory to H2-receptor antagonists and to compare the recurrence rates after the two treatments." | 5.08 | Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication. ( Avsar, E; Gültekin, O; Kalayci, C; Kiziltas, S; Lawrence, R; Tözün, N; Ulusoy, NB, 1996) |
| "To determine the effect of Helicobacter pylori eradication with omeprazole and amoxycillin, with or without metronidazole, on the 12-month course of duodenal ulcer disease." | 5.08 | Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole. ( Axon, AT; Bate, CM; Bell, GD; Martin, JL; Richardson, PD; Taylor, MD; Tildesley, G, 1996) |
| " Eighty-eight patients with healed erosive/ulcerative oesophagitis and relief of heartburn after pre-treatment with omeprazole received maintenance treatment." | 5.08 | Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease. ( Aalykke, C; Havelund, T; Rasmussen, L, 1997) |
| " pylori from the gastric mucosa, and omeprazole frequently is used for the treatment of duodenal ulcer disease, prompting the interest to investigate rigorously the combination of clarithromycin and omeprazole for eradicating H." | 5.08 | Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. ( Dettmer, A; Fraser, AG; O'Morain, C; Rambow, A; von Fritsch, E, 1996) |
| "The use of omeprazole is more effective than cimetidine in increasing intragastric pH and reducing rebleeding episodes in patients with bleeding peptic ulcers after successful endoscopic therapy." | 5.08 | A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. ( Lee, FY; Lin, HJ; Lo, WC; Perng, CL; Tseng, GY, 1998) |
| " The aim of the present study was to assess efficacy and tolerability of the proton pump inhibitors lansoprazole given at bedtime as compared to ranitidine, both in acute and maintenance treatment of duodenal ulcer." | 5.08 | Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial. ( Dattilo, M; Russo, A, 1997) |
| "In this randomized multicentre study, 267 duodenal ulcer patients were treated for 2 weeks with omeprazole 40 bid (Group A) or 20 mg bid (Group B), respectively, and with amoxycillin 0." | 5.08 | Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study. ( Annibale, B; Bordi, C; Cesana, B; Damilano, I; Franceschi, M; Maconi, G; Pilato, FP, 1997) |
| "Our purpose was to compare the safety and efficacy of lansoprazole 15 mg and 30 mg with placebo in preventing recurrence in 49 patients with a history of gastric ulcer." | 5.08 | Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1998) |
| "In patients with active or a recent history of duodenal ulcer, a 14-day course of lansoprazole-based triple therapy without additional acid suppression therapy is highly effective in the eradication of H." | 5.08 | Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. ( Freston, J; Haber, M; Krause, R; Rose, P; Sahba, B; Schwartz, H; Siepman, N; Weissfeld, A, 1998) |
| "The aim of the present study was to evaluate the efficacy of omeprazole coupled with amoxicillin in the eradication of Helicobacter pylori and healing and prevention of gastric ulcer recurrence." | 5.08 | Helicobacter pylori eradication in the healing and recurrence of benign gastric ulcer: a two-year, double-blind, placebo controlled study. ( Bargiggia, S; Bianchi Porro, G; Cesana, B; Fiocca, R; Franceschi, M; Lazzaroni, M; Maconi, G; Perego, M; Solcia, E, 1997) |
| " pylori infection and duodenal ulcer bleeding were treated with omeprazole (40 mg/day for 4 wk), colloidal bismuth (480 mg/day for 2 wk), amoxicillin (2 g/day for 1 wk), and metronidazole (750 mg/day for 1 wk), and followed up for 48 months." | 5.08 | Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study. ( Macri, G; Milani, S; Passaleva, MT; Salvadori, G; Surrenti, C; Surrenti, E, 1998) |
| "After healing and symptom relief had been obtained on open therapy with lansoprazole 30 mg daily, 103 patients with reflux oesophagitis grade 1 or 2 were randomized to maintenance therapy with lansoprazole 15 or 30 mg daily, and time until recurrence of symptoms and/or endoscopic changes was recorded." | 5.08 | Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. ( Berstad, A; Hatlebakk, JG, 1997) |
| "To investigate the efficacy of daily maintenance treatment with omeprazole 10 mg in reducing the relapse rate of healed erosive oesophagitis." | 5.08 | Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo. ( Bardhan, KD; Bishop, A; Brooks, A; Cherian, P; D'Silva, J; Gillon, KR; Jones, RB; Morris, P; Patterson, J; Polak, J; Thompson, M; Vaishnavi, A; Wason, C, 1998) |
| "In order to investigate whether chronic duodenal ulcer disease is a consequence of disturbed mucosal turnover and growth factor expression, we studied 16 patients with duodenal ulcers before, during, and after endoscopic healing with lansoprazole or sucralfate." | 5.08 | Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans. ( Marks, IN; O'Keefe, SJ; Ogden, J; Winter, T; Zhang, T, 1998) |
| "We investigated the relationship between histological maturity of healed duodenal ulcer and ulcer recurrence after treatment with omeprazole or cimetidine for 4 weeks." | 5.07 | Histological maturity of healed duodenal ulcer and ulcer recurrence after treatment with omeprazole or cimetidine. ( Chen, SH; Liao, CH; Lien, GS; Pan, S, 1994) |
| "The goals of this study were to assess the effectiveness of a new triple therapy consisting of amoxicillin and metronidazole with plaunotol in the eradication of Helicobacter pylori infection in humans, and to determine whether this treatment regimen reduces the rate of recurrence of gastric ulcer in patients infected with H." | 5.07 | Bismuth-free triple therapy for eradicating Helicobacter pylori and reducing the gastric ulcer recurrence rate. ( Karita, M; Morshed, MG; Okita, K; Ouchi, K, 1994) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 5.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| " pylori-positive duodenal ulcers were randomized to receive either triple therapy for 1 wk plus omeprazole for 4 wk (Triple+OMP) (n = 78), or omeprazole alone (OMP) for 4 wk (N = 77)." | 5.07 | One-year follow-up of duodenal ulcers after 1-wk triple therapy for Helicobacter pylori. ( Cheng, AF; Chung, SC; Hosking, SW; Li, AK; Ling, TK; Sung, JJ; Yung, MY, 1994) |
| "Duodenal ulcer relapse rates after therapy with sucralfate or bismuth are lower than those after H2-receptor antagonist therapy." | 5.07 | Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates. ( Jaskiewicz, K; Lastovica, A; Le Roux, E; Louw, JA; Lucke, W; Marks, IN; Winter, T; Zak, J, 1992) |
| " In this 2:1 randomized, double-blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out-patients suffering from uncomplicated duodenal ulcer." | 5.07 | Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. ( Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA, 1992) |
| "The present study determined whether the rate of relapse of duodenal ulcer was reduced after ulcer healing with omeprazole compared with ranitidine or placebo." | 5.07 | Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: a double-blind, multicenter, 6-month study. The Omeprazole Duodenal Ulcer Study Group. ( Cagliola, AJ; Colon-Pagan, J; Graham, DY; Johnson, TL; Marks, JW; McCullough, AJ; Morse, RS; Sklar, M; Stone, RC; Walsh, JH, 1992) |
| "Acid secretory responses and parietal cell sensitivity (PCS) have been studied in 21 duodenal ulcer patients before and after successful treatment with omeprazole (n = 7), sucralfate (n = 7), or Maalox (n = 7)." | 5.07 | Acid secretory responses and parietal cell sensitivity following duodenal ulcer healing with omeprazole, sucralfate, and Maalox. ( Bridger, S; Johnston, DA; Marks, IN; Tigler-Wybrandi, NA; Young, GO; Zak, J, 1991) |
| "Forty-four patients with esophagitis refractory to standard H2-blocker therapy, who had healed after a 4- to 16-wk course with either 20-40 mg omeprazole or ranitidine at doses of 300-600 mg daily in a randomized double-blind study, commenced a 3-month maintenance course of therapy with 40 mg bid famotidine." | 5.07 | High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study. ( Bianchi-Porro, G; Bonavina, L; Pace, F; Peracchia, A; Sangaletti, O; Termini, R; Vigneri, S, 1991) |
| "In a double-blind, parallel-group clinical trial of 195 patients with duodenal ulcers who after a short-term study had relief of pain and healed ulcers proved endoscopically, 65 were randomized to receive 20 mg omeprazole 3 days a week (once in the morning from Friday to Sunday), 64 to receive 10 mg omeprazole once daily in the morning, and 66 to receive placebo for up to 6 months." | 5.07 | Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial. ( Andersen, BN; Eriksen, J; Hansen, J; Havelund, T; Kjaergaard, J; Lauritsen, K; Laursen, LS; Rask-Madsen, J; Rehfeld, JF, 1991) |
| "In a Swedish-Norwegian multicentre study patients with endoscopically verified duodenal ulcers (greater than 5 mm) were randomized to 2 or 4 weeks of treatment with either 20 mg omeprazole once daily or 300 mg ranitidine once daily." | 5.07 | Two and four weeks' treatment for duodenal ulcer. Symptom relief and clinical remission comparing omeprazole and ranitidine. Scandinavian Clinics for United Research. ( Carling, L; Engström, G; Glise, H; Hallerbäck, B; Martinson, J; Solhaug, JH; Unge, P, 1991) |
| "To investigate the efficacy of standard and low dosage of omeprazole in the healing of duodenal ulcer, 270 patients with endoscopically active duodenal ulcer were randomized to receive omeprazole, 10 mg or 20 mg every morning, or ranitidine, 150 mg twice daily, using the double-dummy technique." | 5.06 | Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: a randomized double-blind study with weekly endoscopic assessment. ( Branicki, FJ; Hui, WM; Lai, CL; Lam, SK; Lau, WY; Lok, AS; Ng, MM; Poon, GP, 1989) |
| "Two hundred and seventeen gastric ulcer patients whose ulcers had healed during omeprazole (30 mg) or cimetidine (1 g) treatment entered a follow-up study for 6 months." | 5.06 | Relapse of gastric ulcers after healing with omeprazole and cimetidine. A double-blind follow-up study. Danish Omeprazole Study Group. ( , 1989) |
| "One hundred and twenty-nine patients were studied with regard to healing of duodenal ulcers with 30 mg omeprazole once daily, recurrence rates after 2 and 4 weeks' treatment in patients with ulcers healed after 2 weeks, and recurrences in rapid and slow healers." | 5.06 | Duodenal ulcer treated with omeprazole: healing and relapse rates. Does treatment duration influence subsequent remission? ( Andersen, OK; Bernklev, T; Farup, PG; Halvorsen, L; Rosseland, AR, 1989) |
| "In a preliminary study to compare the effects of different doses of omeprazole 44 patients with endoscopically diagnosed duodenal ulceration randomly received omeprazole 20 mg, 30 mg, 40 mg, or 60 mg daily for four weeks." | 5.05 | Omeprazole in duodenal ulceration: acid inhibition, symptom relief, endoscopic healing, and recurrence. Cooperative study. ( , 1984) |
| "We conducted a double-blind randomized study of 132 patients to determine whether the new, investigational proton-pump inhibitor, omeprazole (30 mg per day), would accelerate healing and pain relief, as compared with cimetidine (1 g per day), in patients with duodenal ulcer." | 5.05 | Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. ( Andersen, HH; Bendtsen, F; Bytzer, P; Højlund, M; Jensen, KG; Kelbaek, H; Lauritsen, K; Linde, J; Rask-Madsen, J; Rune, SJ, 1985) |
| " pylori infection, indomethacin and their combination affects the healing of gastric ulcers and whether or not such factors provoke a relapse of healed acetic acid ulcers; and 2) whether or not eradication of the bacteria with drugs at specified times after infection prevents the development of mucosal changes, including gastric adenocarcinoma." | 4.81 | [Pharmacological study on the pathological changes of the gastric mucosa in Helicobacter pylori-infected Mongolian gerbils]. ( Ebata, M; Keto, Y; Okabe, S, 2001) |
| "Aim of this overview was to evaluate the main clinical trials with lansoprazole published from 1997 to 1999 in English-language journals, regarding gastroesophageal reflux disease, peptic ulcer, NSAID-induced ulcer, and ZES." | 4.80 | [Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999]. ( Capurso, L; Dobrilla, G, 2000) |
| "A 53-year old female patient with duodenal ulcer and Helicobacter pylori infection was treated three times with a proton pump inhibitor-based triple therapy, such as lansoprazole-clarithromycin-amoxicillin (INN, amoxicilline) and lansoprazole-minocycline-cefaclor." | 4.80 | Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. ( Furuta, T; Hanai, H; Ishizaki, T; Ohashi, K; Shirai, N; Takashima, M; Xiao, F, 2000) |
| "Individual data from 1154 patients included in five independently conducted, randomized, long-term clinical trials of the efficacy of different dosage regimens of omeprazole, standard ranitidine treatment and placebo for the prevention of relapse of oesophagitis were pooled for this meta-analysis." | 4.79 | Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. ( Carlsson, R; Dent, J; Frison, L; Galmiche, JP; Lundell, L, 1997) |
| "To evaluate the effect of drug interaction between omeprazol and clopidogrel in hospital readmission of patients with acute coronary syndrome (ACS)." | 3.80 | [Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study]. ( Amariles, P; Angulo, NY; Betancourth, PM; Ceballos, M; Holguín, H, 2014) |
| "Patients who had heartburn twice a week or more were treated with 20 mg omeprazole (OPZ) once daily for 8 wk as an initial therapy (study 1)." | 3.77 | Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan. ( Fujiwara, A; Ishioka, H; Kawahara, Y; Nasu, J; Okada, H; Takenaka, R; Tsuzuki, T; Yamamoto, K; Yoshinaga, F, 2011) |
| "We conducted a retrospective cohort study to assess CV outcomes of 9753 patients taking dual antiplatelet therapy of aspirin plus clopidogrel with or without a PPI after hospitalization for acute coronary syndrome (ACS)." | 3.77 | Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. ( Chen, PF; Hsiao, FY; Huang, WF; Mullins, CD; Tsai, YW; Wen, YW, 2011) |
| "The aim of this study is to assess the prevalence of peptic ulcer rebleeding by comparing patients who received omeprazole versus pantoprazole i." | 3.76 | [Prevalence of rebleeding from peptic ulcer in patients treated with proton pump inhibitors]. ( de Sousa, M; Garrido, A; Iborra, MI; Saperas, E, 2010) |
| "In this retrospective study, high-dose omeprazole reduced the occurrence of rebleeding, need for surgery and mortality due to hemorrhagic shock in patients with high-risk peptic ulcer bleeding, as compared with standard-dose omeprazole." | 3.74 | Continuous infusion of high-dose omeprazole is more effective than standard-dose omeprazole in patients with high-risk peptic ulcer bleeding: a retrospective study. ( Bernard-Chabert, B; DI Martino, V; Massard, J; Poynard, T; Ratziu, V; Simon-Rudler, M; Thabut, D, 2007) |
| "To evaluate the omeprazole maintenance therapy in patients with recurrent ulcer bleeding after surgery for duodenal ulcer." | 3.73 | Omeprazole maintenance therapy prevents recurrent ulcer bleeding after surgery for duodenal ulcer. ( Demertzis, K; Emmanuel, T; Ladas, SD; Polymeros, D; Tassios, P; Triantafyllou, K, 2006) |
| "The efficacy of a paste formulation of the H+, K+, -ATPase inhibitor omeprazole was evaluated in standardbred racehorses for the treatment and prevention of gastric ulcers." | 3.72 | Efficacy of a paste formulation of omeprazole for the treatment of naturally occurring gastric ulcers in training standardbred racehorses in Canada. ( Alva, R; Dionne, R; Doucet, MY; Ericsson, G; Vrins, AA, 2003) |
| "A 3-month observational study was conducted in an OTC setting to determine whether consumers could (1) correctly self-select to use omeprazole for frequent heartburn, (2) comply with a product label that calls for 14 consecutive days of once-daily dosing, and (3) use more than 14 doses of medication only under the advice of a physician." | 3.72 | Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. ( Allgood, G; Allgood, L; Fendrick, AM; Grender, J; Peura, D; Schachtel, B; Shaw, M, 2004) |
| "Six captive cheetahs (Acinonyx jubatus) with severe gastritis diagnosed by gastric endoscopy and mucosal histopathology were treated with omeprazole, metronidazole, and amoxicillin for 3 wk." | 3.72 | Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis. ( Burroughs, R; Lane, E; Lobetti, R, 2004) |
| " We examined the roles of TNF-alpha and dynamics of chemokine expression in gastric ulceration including ulcer recurrence and indomethacin-induced injury." | 3.72 | Monocyte chemotactic protein-1 regulates leukocyte recruitment during gastric ulcer recurrence induced by tumor necrosis factor-alpha. ( Arakawa, T; Fujiwara, Y; Hamaguchi, M; Higuchi, K; Matsumoto, T; Shiba, M; Tominaga, K; Watanabe, T, 2004) |
| "Omeprazole is an effective long-term drug for gastroesophageal reflux disease after failed fundoplication in children." | 3.71 | Omeprazole maintenance therapy for gastroesophageal reflux disease after failure of fundoplication. ( Blair, GK; Israel, DM; Pashankar, D, 2001) |
| " pylori infection, indomethacin, and their combination affects the healing of gastric ulcers and whether or not such factors provoke a relapse of healed gastric ulcers in Mongolian gerbils." | 3.71 | Influence of Helicobacter pylori infection on healing and relapse of acetic acid ulcers in Mongolian gerbils. ( Ebata, M; Keto, Y; Okabe, S; Tomita, K, 2002) |
| " Seventeen patients with apparently complete endoscopic and histological eradication of Barrett's oesophagus were re-evaluated at one year; eight (47%) disclosed relapsing islands of Barrett metaplasia despite continuous omeprazole therapy (10-40 mg/day)." | 3.70 | Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. ( Cremer, M; Delhaye, M; Devière, J; Peny, MO; Van Laethem, JL, 1998) |
| " pylori-infected patients with duodenal ulcer were treated with either omeprazole or famotidine plus two antibiotics for 2 wk." | 3.70 | The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. ( Acevedo, C; Duarte, I; Figueroa, C; Fuster, F; Giancaspero, R; Hola, K; Rollan, A; Schulz, M, 2000) |
| " pylori with omeprazole and amoxicillin, the skin changes, gastric complaints, and proteinuria disappeared." | 3.69 | Schönlein-Henoch purpura associated with gastric Helicobacter pylori infection. ( Borchard, F; Goerz, G; Megahed, M; Reinauer, H; Reinauer, S; Ruzicka, T; Susanto, F, 1995) |
| "The efficacy of omeprazole 20 mg a day was assessed against ranitidine 150 mg twice a day in the healing and relapse of duodenal ulcer." | 3.69 | Healing and relapse rates of duodenal ulcer with omeprazole vs ranitidine. ( Ahmed, W; Alam, SE; Qureshi, H; Zuberi, SJ, 1995) |
| "We retrospectively investigated the efficacy of high dose omeprazole compared to a combined therapy of famotidine, pirenzepine and antacid for acute upper gastrointestinal hemorrhage (AUGIH) also adjuvant to endoscopic injection therapy if indicated." | 3.69 | [High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison]. ( Busam, J; Garbe, WE, 1994) |
| "For a significant number of patients with severe or refractory gastroesophageal reflux disease, maintenance treatment with omeprazole and reflux surgery (Nissen fundoplication) are alternative treatment options." | 3.69 | Cost effectiveness of medical versus surgical treatment in patients with severe or refractory gastroesophageal reflux disease in the Netherlands. ( Ament, AJ; Dallemagne, B; Go, PM; Hameeteman, W; Van Den Boom, G, 1996) |
| "Empiric omeprazole therapy is a reasonable, initial approach to patients with suspected gastroesophageal reflux-related posterior laryngitis." | 3.69 | Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. ( Delgaudio, JM; Grist, WJ; Gussack, G; Waring, JP; Wo, JM, 1997) |
| "The aim of this study is to propose a regimen of omeprazole 20 mg twice weekly for the prevention of duodenal ulcer (DU) relapse." | 3.68 | [Study on omeprazole 20 mg twice weekly in prevention of duodenal ulcer relapse]. ( Bei, L; Chen, SP; Wen, SH, 1993) |
| "Biopsies from the stomachs (antrum and corpus) of 201 patients with peptic ulcers or reflux oesophagitis were retrospectively investigated for the effect of treatment with omeprazole on the elimination of Helicobacter pylori (HP) and on gastritis." | 3.68 | Elimination of Helicobacter pylori under treatment with omeprazole. ( Bethke, B; Stolte, M, 1990) |
| "In case of symptom recurrence, an endoscopy was performed." | 2.75 | Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse. ( Bytzer, P; Reimer, C, 2010) |
| "omeprazole was 6." | 2.74 | Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Shah, AH; Sodhi, JS; U-Saif, R; Yatoo, GN; Zargar, SA, 2009) |
| "Relapse was defined as the recurrence of macroscopic esophageal lesions." | 2.73 | Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? ( Boccia, G; Buonavolontà, R; Manguso, F; Miele, E; Staiano, A, 2007) |
| "A total of 119 Japanese patients with recurrent reflux oesophagitis underwent cytochrome P450 2C19 genotyping prior to receiving daily omeprazole 10 mg or 20 mg for 6-12 months, during which adverse event frequency, serum gastrin levels and endoscopic findings were monitored." | 2.71 | Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. ( Aoyama, N; Arakawa, T; Chida, N; Fujimoto, K; Hamada, S; Hoshino, E; Inoue, M; Kawahara, Y; Konda, Y; Maekawa, T; Mine, T; Mitachi, Y; Nagai, T; Nakajima, M; Ohkusa, T; Sato, N; Seno, H; Shimatani, T; Tadokoro, K; Yoshida, N, 2005) |
| "There were no recurrences of Schatzki's ring in the group of patients with documented GERD (follow-up [mean +/- SD]: 43." | 2.71 | Long-term acid suppressive therapy may prevent the relapse of lower esophageal (Schatzki's) rings: a prospective, randomized, placebo-controlled study. ( Avgerinos, A; Bergele, C; Karamanolis, G; Mantides, A; Papadopoulou, E; Sgouros, SN; Stefanidis, G; Vassiliadis, K; Vlachogiannakos, J, 2005) |
| "pylori at 6 wk were infected at 1 yr (recurrence rates 10." | 2.70 | Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure. ( Figueroa, LS; Guarner, J; Halperin, D; Herrera-Goepfert, R; Ley, C; Mohar, A; Parsonnet, J, 2002) |
| "39 patients with Barrett's esophagus, seven of them with low-grade dysplasia, underwent APC and received 40 mg omeprazole daily for eradication of the metaplastic epithelium." | 2.70 | Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. ( Cremer, M; Devière, J; Kahaleh, M; Nagy, N; Van Laethem, JL, 2002) |
| " We performed serial endoscopy, checked for adverse events, and laboratory values." | 2.70 | Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. ( Bardhan, KD; Bishop, AE; Cherian, P; Fischer, R; Lühmann, R; McCaldin, B; Morris, P; Ng, W; Perry, MJ; Polak, JM; Romanska, H; Rowland, A; Schneider, A; Thompson, M, 2001) |
| "Omeprazole was discontinued at 8 weeks and patients were followed up for a further 10 months." | 2.70 | Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. ( Axon, AT; Bardhan, C; Brown, L; Dixon, MF; Moayyedi, P; Young, L, 2001) |
| "Active duodenal ulcer recurrence was identified in seven of 23 H." | 2.70 | Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer. ( Choi, IJ; Jung, HC; Kim, BG; Kim, JS; Kim, SG; Park, MJ; Song, IS, 2002) |
| "Endoscopic therapy reduces the recurrence of bleeding from actively bleeding peptic ulcers and those with visible vessels." | 2.70 | Recurrent bleeding from peptic ulcer associated with adherent clot: a randomized study comparing endoscopic treatment with medical therapy. ( Bleau, BL; Bracy, WP; Fleischer, DE; Gostout, CJ; Harford, WV; Keate, RF; Shaw, MJ; Sherman, KE, 2002) |
| "Omeprazole was better tolerated than misoprostol." | 2.69 | Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. ( Barkun, A; Hawkey, CJ; Karrasch, JA; Swannell, AJ; Szczepañski, L; Walker, DG; Yeomans, ND, 1998) |
| " Dosing was adjusted by monitoring intragastric pH, and esophagoscopy was repeated after 8-12 weeks of omeprazole treatment." | 2.69 | Histological esophagitis: clinical and histological response to omeprazole in children. ( Calenda, KA; Dayal, Y; Mobassaleh, M; Strauss, RS, 1999) |
| "pylori recurrence rate." | 2.69 | [Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment]. ( Iijima, K; Kato, K; Ohara, S; Sekine, H, 1999) |
| "Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+, K+-ATPase, necessary for the final step in gastric acid secretion." | 2.69 | Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up. ( Eloff, FP; Fischer, R; Grundling, HD; Honiball, PJ; Louw, JA; Simjee, AE; Spies, SK; Theron, I; Van Rensburg, CJ; Van Zyl, JH, 1999) |
| "pylori eradication rate and ulcer recurrence rate were compared." | 2.69 | Assessment of decisions in the treatment of Helicobacter pylori-related duodenal ulcer: a cost-effectiveness study. ( Chen, J; Chen, SY; Wang, JY; Zhang, SS; Zhang, XD, 1999) |
| "The ulcer recurrences appeared in patients with H." | 2.69 | [Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication]. ( Mach, T; Zahradnik-Bilska, J, 1999) |
| "Eradication of H." | 2.69 | Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. ( Chan, AC; Chung, SC; Lam, YH; Lau, JY; Lau, WY; Law, BK; Lee, DW; Ling, TK; Ng, EK; Sung, JJ; To, KF; Yung, MY, 2000) |
| "Rabeprazole is a new PPI with demonstrated efficacy in both the acute and maintenance treatment of erosive GERD." | 2.69 | Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. ( Beker, JA; Bjaaland, T; Dekkers, C; Finnegan, V; Humphries, TJ; Thjodleifsson, B, 2000) |
| "Omeprazole is a valuable therapeutic instrument to detect and treat patients with GERD in general practice." | 2.69 | High dose proton pump inhibitor response as an initial strategy for a clinical diagnosis of gastro-oesophageal reflux disease (GERD). Swedish multi-centre group in primary health care. ( Brun, J; Sörngård, H, 2000) |
| "Omeprazole was significantly more effective than cisapride (P = 0." | 2.68 | A comparison of five maintenance therapies for reflux esophagitis. ( Badalamenti, S; Battaglia, G; Di Mario, F; Leandro, G; Mela, GS; Pantalena, M; Pilotto, A; Savarino, V; Termini, R; Vigneri, S, 1995) |
| "We investigated the eradication and recurrence rate of Helicobacter pylori-infected gastric ulcer patients by combination therapies." | 2.68 | Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients. ( Fukuda, Y; Okui, M; Shimoyama, T; Tonokatsu, Y; Yamamoto, I, 1995) |
| " HP was eradicated by combined treatment with high-dose omeprazole (2 x 40 mg) and amoxicillin (2 x 1,000 mg; n = 27) administered for 10 days (OME + AMX); alternatively, patients were treated with omeprazole monotherapy (OME) using the same dosage (n = 25)." | 2.68 | Two-year follow-up of duodenal ulcer patients treated with omeprazole and amoxicillin. ( Bayerdörffer, E; Dirschedl, P; Hatz, R; Höchter, W; Lehn, N; Mannes, GA; Miehlke, S; Ruckdeschel, G; Sommer, A; Weingart, J, 1995) |
| "pylori is associated with low recurrence rates." | 2.68 | Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. ( Giannikos, N; Karameris, A; Mavrogeorgis, A; Rallis, E; Rokkas, T, 1995) |
| "Each omeprazole regimen was superior to placebo in preventing both symptomatic relapse (life table analysis, p < 0." | 2.68 | Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. ( Bate, CM; Booth, SN; Crowe, JP; Hepworth-Jones, B; Keeling, PW; Mountford, RA; Richardson, PD; Taylor, MD, 1995) |
| "Lansoprazole was significantly superior to placebo in maintaining healing and preventing recurrence of symptoms." | 2.68 | Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. ( Avner, D; Haber, M; Lanza, F; Robinson, M, 1996) |
| "91%)." | 2.68 | Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients. ( Acuña, R; Albornoz, V; Figueroa, G; Portell, DP; Toledo, MS; Troncoso, M; Vigneaux, J, 1996) |
| "Cure of HP infection reduces the recurrence of peptic ulcer and of rebleeding from ulcer disease more effectively than does long-term maintenance therapy." | 2.68 | Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. ( Cantero, J; Gómez-Cedenilla, A; Grávalos, RG; Pajares, JM; Santander, C, 1996) |
| "Some recent studies have reported high recurrence rates after apparent cure." | 2.68 | Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy. ( De Boer, WA; Driessen, WM; Geuskens, LM; Lai, JY, 1996) |
| "Cumulative recurrence rates at six months did not statistically differ among the three different groups (27% in H pylori negative, 46% in H pylori positive, and 31% in those where H pylori was eradicated during the healing phase), although a numerical trend in favour of a higher recurrence rate in infected patients was evident." | 2.68 | Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy. ( Bianchi Porro, G; Caruso, I; Imbesi, V; Montrone, F; Parente, F, 1996) |
| "pylori infection and the ulcer recurrence rate after 1 year were investigated." | 2.68 | Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients. ( Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Koshiyama, T; Kudo, M; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H, 1996) |
| "Shallow duodenal ulcers were noted in three patients at 1-year follow-up, two of whom admitted to taking non-steroidal anti-inflammatory drugs (NSAIDs); H." | 2.68 | Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up. ( Goh, KL; Navaratnam, P; Peh, SC, 1996) |
| "Both omeprazole regimens were superior to placebo in preventing recurrence of symptoms (P < 0." | 2.68 | Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi-centre double-blind study. ( Behar, J; Berman, R; Dayal, Y; Hirschowitz, BI; Kranz, KR; Peterson, WL; Robinson, M; Roufail, W; Sabesin, SM; Simon, TJ; Sontag, SJ; Tarnawski, A; Wu, WC, 1997) |
| "Gastro-oesophageal reflux disease (GORD) is a frequent cause for consultation in general practice and is a chronically relapsing disease." | 2.68 | Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. ( Copeman, MB; Hole, J; Newland, RD; Patel, AC; Turbitt, ML; Venables, TL, 1997) |
| "For H." | 2.68 | Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. ( Bardhan, KD; Graham, DY; Hunt, RH; O'Morain, CA, 1997) |
| "Time to ulcer recurrence was significantly longer (P < 0." | 2.68 | Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Jhala, N; Lanza, F; Silvers, D; Winters, J, 1997) |
| "Relapses were re-treated with omeprazole 40 mg; upon rehealing, patients were put on maintenance omeprazole 20 mg daily for up to 4." | 2.68 | Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment. ( Bardhan, KD; Bishop, A; Brooks, A; Cherian, P; D'Silva, J; Gillon, KR; Jones, RB; Manek, S; Morris, P; Parkin, S; Patterson, J; Polak, J; Thompson, M; Vaishnavi, A, 1997) |
| "Patients with reflux esophagitis have rapid relapses after treatment withdrawal." | 2.67 | Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. ( Carling, L; Edwin, B; Glise, H; Hallerbäck, B; Havu, N; Lundberg, K; Lyrenäs, E; Unge, P, 1994) |
| " No significant pathological findings were noted, and no adverse events were attributable to the study treatments." | 2.67 | Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. ( Dent, J; Hetzel, DJ; Mackinnon, M; Narielvala, FM; Reed, W; Shearman, DJ; Solcia, E; Yeomans, ND, 1994) |
| "pylori-positive after treatment, and duodenal ulcer relapsed in 16 out of 25 (64%) patients within the median follow-up of 18 months." | 2.67 | Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. ( Bayerdörffer, E; Dirschedl, P; Hatz, R; Höchter, W; Lehn, N; Mannes, GA; Ruckdeschel, G; Sommer, A; Stolte, M; Weingart, J, 1993) |
| "Those without recurrence during this treatment were followed up for another 6 months." | 2.67 | Prevention of duodenal ulcer recurrence with penicillin. A double-blind, placebo-controlled trial. ( Bonnevie, O; Bremmelgaard, A; Eriksen, J; Hansen, JM; Jensen, TG; Justesen, T; Rune, SJ; Scheibel, J; Thomsen, OO; Vilien, M, 1993) |
| " In conclusion, omeprazole was far superior to ranitidine in preventing recurrence, a goal achieved without adverse events and significant abnormalities in the oxyntic mucosal exocrine or endocrine cells but with a moderate increase in basal gastrin levels." | 2.67 | Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. ( Backman, L; Ekström, P; Enander, LK; Falkmer, S; Fausa, O; Grimelius, L; Havu, N; Lind, T; Lönroth, H; Lundell, L, 1991) |
| " This therapeutic advantage was achieved without adverse events and without significant abnormalities in the endocrine or exocrine cell population of the oxyntic mucosa." | 2.67 | Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. ( Lundell, L, 1990) |
| "Omeprazole is a highly effective treatment for peptic esophagitis." | 2.66 | Healing and relapse of severe peptic esophagitis after treatment with omeprazole. ( Beveridge, BR; Dent, J; Gibson, GG; Hetzel, DJ; Laurence, BH; Mackinnon, M; McCarthy, JH; Mitchell, B; Narielvala, FM; Reed, WD, 1988) |
| " If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended." | 2.46 | [Dilemma between gastroprotection and cardiovascular prevention]. ( Kandulski, A; Malfertheiner, P; Venerito, M, 2010) |
| "Lansoprazole has a wide margin of safety and is well tolerated when administered as monotherapy in short- and long-term clinical trials." | 2.41 | Lansoprazole for maintenance of remission of erosive oesophagitis. ( Ballard, ED; Freston, JW; Huang, B; Jackson, RL, 2002) |
| "Although relatively rare, GERD patients refractory to medical therapy remain a challenge for the clinician." | 2.40 | Medical therapy. Management of the refractory patient. ( Castell, DO; Hatlebakk, JG; Katz, PO, 1999) |
| "Gastroesophageal reflux disease (GERD) is a common disorder which may result in esophageal ulcers, erosions, strictures and motility disorders if it is not treated promptly." | 2.39 | The treatment of gastroesophageal reflux disease. ( Kaplan, B; Koppelo, KL, 1994) |
| "Although ulcer recurrence and complications can be prevented, many patients with peptic ulcer disease fail to receive the benefits of modern therapeutic regimens." | 2.39 | Review article: Helicobacter pylori eradication--understandable caution but no excuse for inertia. ( Penston, JG, 1994) |
| "Reflux esophagitis is a chronic condition and after stopping antisecretory treatment, including lansoprazole, most patients relapse in terms of symptoms and endoscopical lesions, which suggests the need for long-term treatment." | 2.38 | Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. ( Di Fede, F; Dobrilla, G, 1993) |
| "Omeprazole, 20 mg daily, was found to be a highly effective maintenance therapy in patients with ulcerative oesophagitis, keeping 67-89% of patients in remission for 1 year, compared with 10-25% of patients treated with ranitidine, 150 mg twice daily." | 2.38 | Controlled clinical trials of omeprazole in the long-term management of reflux disease. ( Hetzel, DJ, 1992) |
| " Conventional dosing with H2-receptor antagonists has been successful in only about 50% of the patients with reflux esophagitis." | 2.38 | The role of omeprazole in healing and prevention of reflux disease. ( Klinkenberg-Knol, EC, 1992) |
| "Omeprazole has a simple treatment regimen: 20 mg once daily is recommended in the routine treatment of DU, GU and RO." | 2.38 | Treatment of acid-related disorders with gastric acid inhibitors: the state of the art. ( Blum, AL, 1990) |
| "Omeprazole has been shown to provide more rapid symptom relief and to heal ulcers more quickly and reliably than H2-receptor antagonists in duodenal ulcer, gastric ulcer and reflux oesophagitis." | 2.38 | Clinical development programme for omeprazole. ( Walan, A, 1990) |
| "Studying role of duodenogastric reflux (DGR) in pathogenesis and sanogenesis of duodenal ulcer (DU)." | 1.37 | [Characteristics of duodenogastric reflux in duodenal ulcer patients and its dynamics after Helicobacter pylori eradication]. ( Kolesnikova, IIu; Liubskaia, LA; Volkov, VS, 2011) |
| "Eight patients (17%) with relapse of dysphagia were referred to laparoscopic Heller myotomy with no surgical complication." | 1.36 | Combined treatment of achalasia - botulinum toxin injection followed by pneumatic dilatation: long-term results. ( Dolina, J; Hep, A; Kroupa, R; Matyasova, Z; Mrazova, J; Novotny, I; Prokesova, J; Sedmik, J; Valek, V, 2010) |
| " Application of a combined preparation, consisting of 20 mg of omeprazol, 500 mg of clarithromycin, 1000 mg amoxicillin, in a standard dosage of 3 tablets twice a day during 7 days have permitted to achieve the H." | 1.35 | [Antihelicobacteric therapy for the patients with recurrent complicated postoperative gastroduodenal ulcer: indications, principles of conduction, efficacy]. ( Buka, GIu; Veligotskiĭ, NN, 2009) |
| " The ulcers scarred after the long-term administration of a proton pump inhibitor (PPI), but recurred after the suspension." | 1.35 | Recurrent peptic ulcer disease in a pediatric patient with type 1 neurofibromatosis and primary ciliary dyskinesia. ( Di Stefano, V; Francavilla, R; Lionetti, E; Pavone, L; Principi, MB; Ruggieri, M, 2009) |
| "In developing countries the recurrence rate of Helicobacter pylori after successful eradication therapy is as high as 42%, while in developed countries it is estimated to be less than 3%." | 1.35 | Helicobacter pylori recurrence and infection rate in Israeli adults. ( Achiel, K; Hazazi, R; Lederfein, T; Niv, Y; Waked, A, 2008) |
| "Gastroesophageal reflux disease is a common and chronic disorder but long term, prospective studies of the fate of patients seeking medical advice are scarce." | 1.34 | Prospective Acid Reflux Study of Iran (PARSI): methodology and study design. ( Abedi, B; Alimohamadi, SM; Ghotbi, MH; Malekzadeh, R; Mamarabadi, M; Mofid, A; Mostajabi, P; Nasseri-Moghaddam, S; Nouraie, M; Razjouyan, H; Sohrabpour, AA; Sotoudeh, M; Tofangchiha, S, 2007) |
| "Gastroesophageal reflux disease (GERD) is commonly associated with asthma; however, frequency in nonatopic children with asthmatic symptoms is unknown." | 1.33 | Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease. ( Aydoğdu, S; Kasirga, E; Kirmaz, C; Yilmaz, O; Yüksel, H, 2006) |
| "Proton pump inhibitors play an important role in increasing the bioavailability of antibiotics in the gastric mucus by altering gastric volumes and increasing the stability of some antibiotics, e." | 1.33 | Helicobacter pylori: factors affecting eradication and recurrence. ( Vakil, N, 2005) |
| "Seventy-one H." | 1.33 | Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. ( Castro-Fernández, M; Cosme, A; Gisbert, JP; Gómez, B; Herrerías, JM; Luna, M; Monés, J; Olivares, D; Pajares, JM; Sánchez-Pobre, P, 2006) |
| "To characterize posttreatment recurrence of Helicobacter pylori in Peru, 192 adults with H." | 1.32 | Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy. ( Bautista, CT; Berg, DE; Dailide, G; Gilman, RH; Katz, U; Meza, R; Monath, TP; Ogura, M; Razuri, M; Roth, DE; Soto, G; Taylor, DN; Velapatiño, B, 2003) |
| "Radical treatment of GERD allows the pulmonologist to perform correct respiratory treatment and to prevent the development chronic and life-threatening complications." | 1.32 | Outcome of laparoscopic Nissen-Rossetti fundoplication in children with gastroesophageal reflux disease and supraesophageal symptoms. ( Castagnetti, M; Gentilino, V; Jasonni, V; Martino, F; Mattioli, G; Montobbio, G; Pini Prato, A; Sacco, O, 2004) |
| "To assess both acid gastro-oesophageal reflux (GOR) suppression in patients with Barrett's oesophagus on proton-pump inhibitors (PPI) and the predictive value of symptoms." | 1.31 | Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy. ( Bale, R; Basu, KK; de Caestecker, JS; West, KP, 2002) |
| "pylori and oesophagitis is mediated by the effect of H." | 1.31 | Should we eradicate Helicobacter pylori in patients with recurrent gastro-oesophageal reflux disease? ( Bianchi Porro, G; Pace, F, 2000) |
| "Cumulative ulcer recurrence rate for 12 months, respectively for patients with eradication success and failure, was 2." | 1.31 | [Effects of Helicobacter pylori eradication on the recurrence of gastric ulcer during a 12-month follow up]. ( Bermejo, F; Boixeda, D; Defarges, V; García Plaza, A; Gisbert, JP; Martín de Argila, C; Sanz, JM, 2000) |
| "Treatment with omeprazole, amoxicillin, and clarithromycin resulted in eradication of the infection in all and in resolution of the clinical symptoms in 15 (80%) of 19 patients who had a follow-up examination." | 1.31 | Helicobacter pylori infection in recurrent abdominal pain. ( Braegger, CP; Frank, F; Stallmach, T; Stricker, T, 2000) |
| "It was concluded that the recurrence of HP infection is low at the end of one year after successful eradication therapy in this urban East Asian population." | 1.31 | Recurrence of Helicobacter pylori infection and duodenal ulcer relapse, following successful eradication in an urban east Asian population. ( Fock, KM; Khor, CJ; Ng, A; Ng, TM; Sim, CS; Tan, AL; Teo, EK, 2000) |
| "Gastric acid is required for recurrence of gastric ulcers caused by IL-1beta, and gastric acid stimulates the inflammatory process in scarred mucosa during ulcer recurrence." | 1.31 | Acid regulates inflammatory response in a rat model of induction of gastric ulcer recurrence by interleukin 1beta. ( Arakawa, T; Fujiwara, Y; Higuchi, K; Tominaga, K; Watanabe, T, 2001) |
| "A patient with von Willebrand's disease had recurrent gastrointestinal bleeding from angiodysplasia, with inadequate response to von Willebrand factor substitution, medical and endoscopic treatment, and resection of affected bowel." | 1.31 | Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. ( Meijer, K; Peters, FT; van der Meer, J, 2001) |
| "H pylori was detected in the dental plaque with camphylobacter-like organism test gels." | 1.31 | The relationship between gastric-oral Helicobacter pylori and oral hygiene in patients with vitamin B12-deficiency anemia. ( Avcu, F; Avcu, N; Beyan, C; Kaptan , K; Nevruz, O; Ozyurt, M; Ural, AU; Yalçin, A, 2001) |
| "1 year after drug therapy the recurrence of CDU is revealed in 16." | 1.31 | [Current principles of the use of laparoscopic surgery in gastroduodenal ulcer]. ( Fedorov, AV; Sazhin, VP, 2001) |
| "We determined late recrudescence rates, true reinfection, and ulcer recurrence." | 1.31 | Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. ( Ahmad, MM; Arefin, MS; Bardhan, P; Bauerfeind, P; Beglinger, C; Glatz-Krieger, K; Gyr, N; Hasan, M; Hildebrand, P; Khan, AK; Parvin, S; Rahman, A; Rossi, L; Terracciano, L, 2001) |
| "Omeprazole was also not statistically different from misoprostol for gastric ulcer prevention in those whose NSAID use was complicated by an active H." | 1.31 | Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users. ( Graham, DY, 2002) |
| "Of the 83 smokers, 3 (3." | 1.30 | Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori? ( Chan, FK; Chan, LY; Chung, SC; Lee, YT; Leung, WK; Sung, JJ; Yung, MY, 1997) |
| "The other two approaches prevent more recurrences: waiting to initiate maintenance therapy until symptoms recur once requires an additional $73 for each recurrence prevented whereas maintenance PPI from the outset requires an additional $819 for each recurrence prevented." | 1.30 | Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. ( Harris, RA; Kuppermann, M; Richter, JE, 1997) |
| "The therapeutic approach to gastroesophageal reflux disease (GERD) in intellectually disabled individuals has not been studied extensively." | 1.30 | Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy. ( Bohmer, CJ; Devillé, WL; Klinkenberg-Knol, EC; Meuwissen, SG; Niezen-de Boer, MC; Tuynman, HA; Voskuil, JH, 1997) |
| "If patients experience a symptomatic recurrence on the H2RA strategies, they then receive PPI maintenance." | 1.30 | Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. ( Harris, RA; Kuppermann, M; Richter, JE, 1997) |
| "When omeprazole was re-started she developed fever and acute renal failure, which again settled quickly on discontinuation of omeprazole." | 1.30 | Pyrexia, anaemia and acute renal failure secondary to omeprazole. ( Arnold, IR; Ferner, RE; Landray, MJ; Ringrose, T, 1998) |
| "Omeprazole does increase intragastric pH in bleeding peptic ulcer patients with H." | 1.30 | Will Helicobacter pylori affect short-term rebleeding rate in peptic ulcer bleeding patients after successful endoscopic therapy? ( Chang, FY; Hsieh, YH; Lee, FY; Lee, SD; Lin, HJ; Perng, CL; Tseng, GY, 1999) |
| "After 1 year, no patient had H." | 1.30 | Duodenal ulcer relapse is not always associated with recurrence of H. pylori infection: a prospective three-year follow-up study. ( Annibale, B; D'Ambra, G; Delle Fave, G; Marcheggiano, A; Martino, G; Paoletti, M, 1999) |
| "Those ascribed to gastroesophageal reflux and vocal abuse have a high resolution rate, although some cases need rescue procedures." | 1.30 | Clinical evolution of laryngeal granulomas: treatment and prognosis. ( De Biase, NG; de Lima Pontes, PA; Gadelha, EC, 1999) |
| "She had been suffering from gastroduodenal ulcer for about ten years." | 1.29 | [A case report of prosthetic valve replacement for malfunction of the Hancock valve in mitral position associated with recurrent peptic ulcer and renal dysfunction]. ( Aomi, S; Fujino, S; Hashimoto, A; Hirai, M; Koyanagi, H; Koyanagi, T; Sakahashi, H; Tokunaga, H, 1995) |
| " From these results we conclude that, following endoscopic hemostasis of bleeding ulcers, Omeprazol has no advantage over Ranitidin using our dosage regimes." | 1.29 | [Do proton pump inhibitors after endoscopic control of acute ulcer hemorrhage have an advantage over H2 receptor antagonists?]. ( Barnert, J; Fleischmann, R; Hendrich, H; Prassler, R; Richter, G; Wienbeck, M, 1995) |
| "Duodenal ulcers were healed with omeprazole, 20 mg/day." | 1.29 | Helicobacter pylori eradication in the African setting, with special reference to reinfection and duodenal ulcer recurrence. ( Jaskiewicz, K; Lastovica, AJ; Louw, JA; Lucke, W; Marks, IN; Winter, TA, 1995) |
| "The H." | 1.29 | Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. ( Börsch, G; Labenz, J, 1994) |
| "Duodenal ulcer is a chronic disease with a high risk of relapse--if left untreated, the relapse rate is 50-80% per year (1)." | 1.29 | Prevention of duodenal ulcer relapse by long-term treatment with omeprazole. ( Festen, HP, 1994) |
| " From these data, we conclude that personalized maintenance therapy with omeprazole is the most cost-effective: a dosage of 20 mg/day is extremely effective in maintaining remission, and is therefore most indicated in patients at risk; omeprazole 20 mg/day every-other-day affords better compliance, lower costs and fewer relapses with respect to standard H2-antagonist dosages." | 1.29 | [Evaluation of the cost of maintenance therapy (6 months) with 150 mg ranitidine vs 20 mg omeprazole vs 20 mg omeprazole every other day in duodenal ulcer]. ( Battaglia, G; Chiozzini, G; De Bona, M; De Boni, M; Di Mario, F; Grasso, GA; Pasquino, M; Saggioro, A; Vianello, F, 1993) |
| "Between 1965 and 1990 200 patients were treated for peptic esophageal stricture by surgery or bougienage with antisecretory medication." | 1.29 | Peptic esophageal stricture: is surgery still necessary? ( Bischof, G; Feil, W; Riegler, M; Schiessel, R; Wenzl, E, 1996) |
| " Successful control of reflux disease in these patients was achieved by increasing omeprazole therapy to a regime and dosage that achieved elevation of intragastric pH above 4 throughout the 24-hour period." | 1.28 | Medical therapy of patients with reflux oesophagitis poorly responsive to H2-receptor antagonist therapy. ( Klinkenberg-Knol, EC; Meuwissen, SG, 1992) |
| " All healed with further omeprazole and healing persisted with long-term administration (20 mg/day)." | 1.28 | Bleeding from staple line erosion after esophageal transection: effect of omeprazole. ( Burroughs, AK; Hobbs, KE; Kaye, GL; McCormick, PA; McIntyre, N; Siringo, S, 1992) |
| "No further recurrence with 20 mg omeprazole was found later than six months." | 1.28 | Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. ( Arnold, R; Koop, H, 1991) |
| "Fourteen of 24 patients (58%) had recurrence of endoscopic esophagitis documented between 26 and 300 days from the time of starting maintenance therapy." | 1.28 | Omeprazole in H2 receptor antagonist-resistant reflux esophagitis. ( Beck, IT; Da Costa, LR; Marciano-D'Amore, DA; Paterson, WG, 1990) |
| "Consequently, there was a fast recurrence of aggravation of reflux symptoms and oesophagitis." | 1.28 | Temporary cessation of long-term maintenance treatment with omeprazole in patients with H2-receptor-antagonist-resistant reflux oesophagitis. Effects on symptoms, endoscopy, serum gastrin, and gastric acid output. ( Jansen, JB; Klinkenberg-Knol, EC; Lamers, CB; Meuwissen, SG; Nelis, F, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (3.76) | 18.7374 |
| 1990's | 220 (55.14) | 18.2507 |
| 2000's | 142 (35.59) | 29.6817 |
| 2010's | 21 (5.26) | 24.3611 |
| 2020's | 1 (0.25) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y | 1 |
| Ma, L | 1 |
| Cheng, J | 1 |
| Su, J | 1 |
| Levy, AN | 1 |
| Ali, N | 1 |
| Andrici, J | 1 |
| Hamilton, MJ | 1 |
| Qi, ZW | 1 |
| Lu, HL | 1 |
| Zhang, J | 1 |
| Zhang, SJ | 1 |
| Agudo-Fernández, S | 1 |
| González Blanco, A | 1 |
| Benajah, DA | 1 |
| Lahbabi, M | 1 |
| Alaoui, S | 1 |
| El Rhazi, K | 1 |
| El Abkari, M | 1 |
| Nejjari, C | 1 |
| Amarti, A | 1 |
| Bennani, B | 1 |
| Mahmoud, M | 1 |
| Ibrahimi, SA | 1 |
| Amariles, P | 1 |
| Holguín, H | 1 |
| Angulo, NY | 1 |
| Betancourth, PM | 1 |
| Ceballos, M | 1 |
| Gómez-Torrijos, E | 1 |
| García-Rodríguez, R | 1 |
| Castro-Jiménez, A | 1 |
| Rodríguez-Sanchez, J | 1 |
| Méndez Díaz, Y | 1 |
| Molina-Infante, J | 1 |
| Lau, J | 1 |
| Lind, T | 3 |
| Persson, T | 1 |
| Eklund, S | 1 |
| Felga, GE | 1 |
| Silva, FM | 1 |
| Barbuti, RC | 1 |
| Navarro-Rodriguez, T | 1 |
| Zaterka, S | 1 |
| Eisig, JN | 1 |
| Bago, J | 1 |
| Pevec, B | 1 |
| Tomić, M | 1 |
| Marusić, M | 1 |
| Bakula, V | 1 |
| Bago, P | 1 |
| Veligotskiĭ, NN | 1 |
| Buka, GIu | 1 |
| Tan, VP | 1 |
| Wong, BC | 3 |
| Javid, G | 3 |
| Zargar, SA | 2 |
| U-Saif, R | 1 |
| Khan, BA | 3 |
| Yatoo, GN | 2 |
| Shah, AH | 2 |
| Gulzar, GM | 3 |
| Sodhi, JS | 2 |
| Khan, MA | 1 |
| Kroupa, R | 1 |
| Hep, A | 1 |
| Dolina, J | 1 |
| Valek, V | 1 |
| Matyasova, Z | 1 |
| Prokesova, J | 1 |
| Mrazova, J | 1 |
| Sedmik, J | 1 |
| Novotny, I | 1 |
| Lionetti, E | 1 |
| Francavilla, R | 1 |
| Ruggieri, M | 1 |
| Di Stefano, V | 1 |
| Principi, MB | 1 |
| Pavone, L | 1 |
| He, X | 1 |
| Bennett, AE | 1 |
| Lian, L | 1 |
| Shen, B | 1 |
| Juhász, M | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 2 |
| Rubin, TA | 1 |
| Gessert, CE | 1 |
| Aas, J | 1 |
| Garrido, A | 1 |
| Iborra, MI | 1 |
| Saperas, E | 1 |
| de Sousa, M | 1 |
| Zhang, WP | 1 |
| Ge, HN | 1 |
| Guo, JW | 1 |
| Reimer, C | 1 |
| Bytzer, P | 2 |
| Venerito, M | 1 |
| Kandulski, A | 1 |
| Malfertheiner, P | 3 |
| Këlliçi, I | 1 |
| Kraja, B | 1 |
| Mone, I | 1 |
| Prifti, S | 1 |
| Tsuzuki, T | 2 |
| Okada, H | 1 |
| Kawahara, Y | 2 |
| Takenaka, R | 1 |
| Nasu, J | 1 |
| Ishioka, H | 1 |
| Fujiwara, A | 1 |
| Yoshinaga, F | 1 |
| Yamamoto, K | 1 |
| Hsiao, FY | 1 |
| Mullins, CD | 1 |
| Wen, YW | 1 |
| Huang, WF | 1 |
| Chen, PF | 1 |
| Tsai, YW | 1 |
| Kolesnikova, IIu | 1 |
| Volkov, VS | 1 |
| Liubskaia, LA | 1 |
| Budzyński, J | 1 |
| Pulkowski, G | 1 |
| Suppan, K | 1 |
| Fabisiak, J | 1 |
| Majer, M | 1 |
| Kłopocka, M | 1 |
| Galus-Pulkowska, B | 1 |
| Wasielewski, M | 1 |
| Basu, PP | 1 |
| Rayapudi, K | 1 |
| Pacana, T | 1 |
| Shah, NJ | 1 |
| Krishnaswamy, N | 1 |
| Flynn, M | 1 |
| Lo, GH | 1 |
| Perng, DS | 1 |
| Chang, CY | 1 |
| Tai, CM | 1 |
| Wang, HM | 1 |
| Lin, HC | 1 |
| Jung, HK | 1 |
| Son, HY | 1 |
| Jung, SA | 1 |
| Yi, SY | 1 |
| Yoo, K | 1 |
| Kim, DY | 1 |
| Moon, IH | 1 |
| Lee, HC | 1 |
| Hawkey, CJ | 5 |
| Naesdal, J | 1 |
| Wilson, I | 1 |
| Långström, G | 1 |
| Swannell, AJ | 2 |
| Peacock, RA | 2 |
| Yeomans, ND | 3 |
| Mohar, A | 1 |
| Ley, C | 1 |
| Guarner, J | 1 |
| Herrera-Goepfert, R | 1 |
| Figueroa, LS | 1 |
| Halperin, D | 1 |
| Parsonnet, J | 1 |
| Gorshkov, VA | 1 |
| Fardet, L | 2 |
| Izzedine, H | 2 |
| Ciroldi, M | 2 |
| Tiev, KP | 2 |
| Cabane, J | 2 |
| Basu, KK | 2 |
| Pick, B | 1 |
| Bale, R | 2 |
| West, KP | 2 |
| de Caestecker, JS | 2 |
| Kahaleh, M | 1 |
| Van Laethem, JL | 2 |
| Nagy, N | 1 |
| Cremer, M | 2 |
| Devière, J | 2 |
| Abraham, D | 1 |
| Saltoun, CA | 1 |
| Metz, DC | 1 |
| Bochenek, WJ | 1 |
| Thjodleifsson, B | 2 |
| Rindi, G | 1 |
| Fiocca, R | 5 |
| Humphries, TJ | 2 |
| Morocutti, A | 1 |
| Miller, N | 1 |
| Bardhan, KD | 7 |
| Asaka, M | 4 |
| Kato, M | 3 |
| Sugiyama, T | 2 |
| Satoh, K | 1 |
| Kuwayama, H | 1 |
| Fukuda, Y | 3 |
| Fujioka, T | 1 |
| Takemoto, T | 4 |
| Kimura, K | 2 |
| Shimoyama, T | 4 |
| Shimizu, K | 1 |
| Kobayashi, S | 1 |
| Fedele, E | 1 |
| Manes, G | 1 |
| Menchise, A | 1 |
| de Nucci, C | 1 |
| Balzano, A | 1 |
| Pilotto, A | 3 |
| Leandro, G | 3 |
| Franceschi, M | 4 |
| Eherer, AJ | 1 |
| Habermann, W | 1 |
| Hammer, HF | 1 |
| Kiesler, K | 1 |
| Friedrich, G | 1 |
| Krejs, GJ | 1 |
| Bolling-Sternevald, E | 2 |
| Lauritsen, K | 4 |
| Talley, NJ | 2 |
| Junghard, O | 1 |
| Glise, H | 4 |
| Doucet, MY | 1 |
| Vrins, AA | 1 |
| Dionne, R | 1 |
| Alva, R | 1 |
| Ericsson, G | 1 |
| Sung, JJ | 7 |
| Chan, FK | 3 |
| Lau, JY | 3 |
| Yung, MY | 5 |
| Leung, WK | 3 |
| Wu, JC | 2 |
| Ng, EK | 3 |
| Chung, SC | 6 |
| Jensen, DM | 2 |
| Pisegna, JR | 2 |
| Soto, G | 1 |
| Bautista, CT | 1 |
| Roth, DE | 1 |
| Gilman, RH | 1 |
| Velapatiño, B | 1 |
| Ogura, M | 1 |
| Dailide, G | 1 |
| Razuri, M | 1 |
| Meza, R | 1 |
| Katz, U | 1 |
| Monath, TP | 1 |
| Berg, DE | 1 |
| Taylor, DN | 1 |
| Romero-Gómez, M | 1 |
| Martínez-Delgado, C | 1 |
| Hergueta, P | 1 |
| Navarro, JM | 1 |
| Garrido-Serrano, A | 1 |
| Santos, O | 1 |
| Montojo, C | 1 |
| Füessl, HS | 1 |
| van Rensburg, CJ | 4 |
| Hartmann, M | 1 |
| Thorpe, A | 1 |
| Venter, L | 1 |
| Theron, I | 2 |
| Lühmann, R | 2 |
| Wurst, W | 1 |
| Mattioli, G | 1 |
| Sacco, O | 1 |
| Gentilino, V | 1 |
| Martino, F | 1 |
| Pini Prato, A | 1 |
| Castagnetti, M | 1 |
| Montobbio, G | 1 |
| Jasonni, V | 1 |
| Rifas, DC | 1 |
| Fendrick, AM | 2 |
| Shaw, M | 1 |
| Schachtel, B | 1 |
| Allgood, L | 1 |
| Allgood, G | 1 |
| Grender, J | 1 |
| Peura, D | 1 |
| Meineche-Schmidt, V | 2 |
| Lane, E | 1 |
| Lobetti, R | 1 |
| Burroughs, R | 1 |
| Watanabe, T | 3 |
| Higuchi, K | 3 |
| Hamaguchi, M | 1 |
| Shiba, M | 1 |
| Tominaga, K | 3 |
| Fujiwara, Y | 3 |
| Matsumoto, T | 2 |
| Arakawa, T | 4 |
| Chen, XX | 1 |
| Ou, BY | 1 |
| Wu, XY | 1 |
| Zhou, XL | 1 |
| Tang, HF | 1 |
| Qü, YP | 1 |
| Shang, SQ | 1 |
| Farrell, S | 1 |
| Milliken, I | 1 |
| Doherty, GM | 1 |
| Murphy, JL | 1 |
| Wootton, SA | 1 |
| McCallion, WA | 1 |
| Oderda, G | 1 |
| Marinello, D | 1 |
| Lerro, P | 1 |
| Kuvidi, M | 1 |
| de'Angelis, GL | 1 |
| Ferzetti, A | 1 |
| Cucchiara, S | 1 |
| Franco, MT | 1 |
| Romano, C | 1 |
| Strisciuglio, P | 1 |
| Pensabene, L | 1 |
| Ashorn, M | 1 |
| Rägö, T | 1 |
| Kokkonen, J | 1 |
| Ruuska, T | 1 |
| Rautelin, H | 2 |
| Karikoski, R | 1 |
| Kollmeier, AP | 1 |
| Eddleston, J | 1 |
| Zuraw, BL | 1 |
| Christiansen, SC | 1 |
| Hung, LC | 1 |
| Suen, BY | 1 |
| Wong, VW | 1 |
| Hui, AJ | 1 |
| Lee, YT | 2 |
| To, KF | 2 |
| Befrits, R | 1 |
| Sjöstedt, S | 1 |
| Tour, R | 1 |
| Leijonmarck, CE | 1 |
| Hedenborg, L | 1 |
| Backman, M | 1 |
| Elizalde, JI | 1 |
| Pérez-Pujol, S | 1 |
| Heras, M | 1 |
| Sionis, A | 1 |
| Casanovas, N | 1 |
| Martorell, T | 1 |
| Lozano, M | 1 |
| González, J | 1 |
| Escolar, G | 1 |
| Sanz, G | 1 |
| Piqué, JM | 1 |
| Arkkila, PE | 1 |
| Seppälä, K | 1 |
| Kosunen, TU | 1 |
| Sipponen, P | 2 |
| Mäkinen, J | 1 |
| Färkkilä, M | 1 |
| Feng, LY | 1 |
| Yao, XX | 1 |
| Jiang, SL | 1 |
| Dohmen, W | 2 |
| Fuchs, W | 2 |
| Armstrong, D | 1 |
| Veldhuyzen van Zanten, SJ | 1 |
| Barkun, AN | 1 |
| Chiba, N | 2 |
| Thomson, AB | 1 |
| Smyth, S | 1 |
| Sinclair, P | 1 |
| Chakraborty, B | 1 |
| White, RJ | 1 |
| Ohkusa, T | 1 |
| Maekawa, T | 1 |
| Nakajima, M | 1 |
| Fujimoto, K | 1 |
| Hoshino, E | 2 |
| Mitachi, Y | 1 |
| Hamada, S | 1 |
| Mine, T | 3 |
| Nagai, T | 1 |
| Aoyama, N | 1 |
| Yoshida, N | 1 |
| Tadokoro, K | 1 |
| Chida, N | 1 |
| Konda, Y | 1 |
| Seno, H | 1 |
| Shimatani, T | 1 |
| Inoue, M | 1 |
| Sato, N | 3 |
| Biswal, N | 1 |
| Ananathakrishnan, N | 1 |
| Kate, V | 1 |
| Srinivasan, S | 1 |
| Nalini, P | 1 |
| Mathai, B | 1 |
| Kaspari, S | 1 |
| Kupcinskas, L | 2 |
| Heinze, H | 1 |
| Berghöfer, P | 1 |
| Yüksel, H | 1 |
| Yilmaz, O | 1 |
| Kirmaz, C | 1 |
| Aydoğdu, S | 1 |
| Kasirga, E | 1 |
| Mine, S | 1 |
| Iida, T | 1 |
| Tabata, T | 1 |
| Kishikawa, H | 1 |
| Tanaka, Y | 1 |
| Horvat, D | 1 |
| Vcev, A | 1 |
| Soldo, I | 1 |
| Timarac, J | 1 |
| Dmitrović, B | 1 |
| Misević, T | 1 |
| Ivezić, Z | 1 |
| Kraljik, N | 1 |
| Sgouros, SN | 2 |
| Vlachogiannakos, J | 2 |
| Karamanolis, G | 1 |
| Vassiliadis, K | 2 |
| Stefanidis, G | 2 |
| Bergele, C | 2 |
| Papadopoulou, E | 1 |
| Avgerinos, A | 1 |
| Mantides, A | 2 |
| Littner, MR | 1 |
| Leung, FW | 1 |
| Ballard, ED | 2 |
| Huang, B | 2 |
| Samra, NK | 1 |
| Ando, T | 1 |
| Minami, M | 1 |
| Mizuno, T | 1 |
| Watanabe, O | 1 |
| Ishiguro, K | 1 |
| Ina, K | 1 |
| Kusugami, K | 1 |
| Nobata, K | 1 |
| Nishiwaki, T | 1 |
| Shimada, M | 1 |
| El-Omar, E | 1 |
| Goto, H | 1 |
| Lai, KC | 2 |
| Chu, KM | 2 |
| Hui, WM | 3 |
| Hu, WH | 2 |
| Wong, WM | 2 |
| Chan, AO | 2 |
| Wong, J | 2 |
| Lam, SK | 3 |
| Vakil, N | 2 |
| Triadafilopoulos, G | 1 |
| Demertzis, K | 1 |
| Polymeros, D | 1 |
| Emmanuel, T | 1 |
| Triantafyllou, K | 1 |
| Tassios, P | 1 |
| Ladas, SD | 2 |
| Lin, HJ | 5 |
| Lo, WC | 3 |
| Cheng, YC | 1 |
| Perng, CL | 4 |
| Gisbert, JP | 3 |
| Luna, M | 1 |
| Gómez, B | 1 |
| Herrerías, JM | 1 |
| Monés, J | 2 |
| Castro-Fernández, M | 1 |
| Sánchez-Pobre, P | 1 |
| Cosme, A | 1 |
| Olivares, D | 1 |
| Pajares, JM | 2 |
| Tran, TT | 1 |
| Quandalle, P | 1 |
| Keyvani, L | 1 |
| Murthy, S | 1 |
| Leeson, S | 1 |
| Targownik, LE | 1 |
| Yilmaz, S | 2 |
| Bayan, K | 2 |
| Dursun, M | 2 |
| Canoruç, F | 2 |
| Kilinç, N | 1 |
| Tüzün, Y | 2 |
| Daniş, R | 1 |
| Ertem, M | 1 |
| Boccia, G | 1 |
| Manguso, F | 1 |
| Miele, E | 1 |
| Buonavolontà, R | 1 |
| Staiano, A | 1 |
| Simon-Rudler, M | 1 |
| Massard, J | 1 |
| Bernard-Chabert, B | 1 |
| DI Martino, V | 1 |
| Ratziu, V | 1 |
| Poynard, T | 1 |
| Thabut, D | 1 |
| Petroianu, G | 1 |
| Stegmeier-Petroianu, A | 1 |
| Niv, Y | 1 |
| Hazazi, R | 1 |
| Waked, A | 1 |
| Lederfein, T | 1 |
| Achiel, K | 1 |
| Siupsinskiene, N | 1 |
| Uloza, V | 1 |
| Pribuisiene, R | 1 |
| Butkus, E | 1 |
| Nasseri-Moghaddam, S | 1 |
| Razjouyan, H | 1 |
| Alimohamadi, SM | 1 |
| Mamarabadi, M | 1 |
| Ghotbi, MH | 1 |
| Mostajabi, P | 1 |
| Sohrabpour, AA | 1 |
| Sotoudeh, M | 1 |
| Abedi, B | 1 |
| Mofid, A | 1 |
| Nouraie, M | 1 |
| Tofangchiha, S | 1 |
| Malekzadeh, R | 1 |
| Misiewicz, JJ | 1 |
| Hirai, M | 1 |
| Hashimoto, A | 1 |
| Aomi, S | 1 |
| Tokunaga, H | 1 |
| Koyanagi, T | 1 |
| Sakahashi, H | 1 |
| Fujino, S | 1 |
| Koyanagi, H | 1 |
| Prassler, R | 1 |
| Hendrich, H | 1 |
| Barnert, J | 1 |
| Richter, G | 1 |
| Fleischmann, R | 2 |
| Wienbeck, M | 1 |
| Labenz, J | 7 |
| Stolte, M | 9 |
| Peitz, U | 2 |
| Tillenburg, B | 1 |
| Köhl, H | 1 |
| Becker, T | 1 |
| Börsch, G | 6 |
| Koop, H | 2 |
| Vigneri, S | 2 |
| Termini, R | 2 |
| Badalamenti, S | 1 |
| Pantalena, M | 1 |
| Savarino, V | 2 |
| Di Mario, F | 3 |
| Battaglia, G | 2 |
| Mela, GS | 2 |
| Hoffenberg, P | 1 |
| Reyes, V | 1 |
| Contreras, L | 1 |
| Giglio, M | 1 |
| Ossa, P | 1 |
| Weitz, JC | 1 |
| Reinauer, S | 1 |
| Megahed, M | 1 |
| Goerz, G | 1 |
| Ruzicka, T | 1 |
| Borchard, F | 1 |
| Susanto, F | 1 |
| Reinauer, H | 1 |
| Munakata, A | 1 |
| Mizuki, I | 1 |
| Akagi, T | 1 |
| Fukuda, S | 1 |
| Ohkawa, K | 1 |
| Yoshida, Y | 2 |
| Aisawa, T | 1 |
| Sakata, Y | 1 |
| Fukushi, M | 1 |
| Yamamoto, I | 1 |
| Okui, M | 1 |
| Tonokatsu, Y | 2 |
| Asaki, S | 2 |
| Sato, A | 1 |
| Sakurada, H | 1 |
| Takeda, T | 1 |
| Hongo, M | 1 |
| Toyota, T | 1 |
| Umeda, N | 1 |
| Sano, J | 1 |
| Miki, K | 1 |
| Yahagi, N | 1 |
| Oka, M | 1 |
| Kimura, M | 1 |
| Miyashita, H | 1 |
| Yasuda, H | 1 |
| Akimoto, K | 1 |
| Katoaka, A | 1 |
| Mashima, H | 1 |
| Tajima, A | 1 |
| Fukujin, H | 1 |
| Tsuchida, T | 1 |
| Takano, T | 1 |
| Nagasawa, J | 1 |
| Ohashi, T | 1 |
| Sakata, J | 1 |
| Haraguchi, Y | 1 |
| Eto, T | 1 |
| Hackelsberger, A | 1 |
| Bisi, G | 1 |
| Dalla Libera, M | 1 |
| Gullini, S | 1 |
| Tartari, V | 1 |
| Caravita, L | 1 |
| Massari, M | 1 |
| Cappellari, L | 1 |
| Zibordi, U | 1 |
| Matarese, V | 1 |
| Ahmed, W | 1 |
| Qureshi, H | 1 |
| Alam, SE | 1 |
| Zuberi, SJ | 1 |
| Garg, PK | 1 |
| Sidhu, SS | 1 |
| Bhargava, DK | 1 |
| Avner, DL | 1 |
| Movva, R | 1 |
| Nelson, KJ | 1 |
| McFarland, M | 1 |
| Berry, W | 1 |
| Erfling, W | 1 |
| Brandt, LJ | 1 |
| Blansky, RL | 1 |
| Kauvar, DR | 1 |
| Kimmig, JM | 1 |
| Miehlke, S | 4 |
| Bayerdörffer, E | 7 |
| Lehn, N | 4 |
| Mannes, GA | 5 |
| Sommer, A | 4 |
| Höchter, W | 4 |
| Weingart, J | 4 |
| Hatz, R | 3 |
| Ruckdeschel, G | 3 |
| Dirschedl, P | 2 |
| Kori, Y | 1 |
| Kato, T | 1 |
| Nakamura, T | 2 |
| Saberi-Firoozi, M | 1 |
| Massarrat, S | 1 |
| Zare, S | 1 |
| Fattahi, M | 1 |
| Javan, A | 1 |
| Etaati, H | 1 |
| Dehbashi, N | 1 |
| Blum, AL | 3 |
| Jorias, I | 1 |
| Leverkus, F | 1 |
| Sollböhmer, M | 1 |
| Bertrams, J | 2 |
| Rokkas, T | 1 |
| Karameris, A | 1 |
| Mavrogeorgis, A | 1 |
| Rallis, E | 1 |
| Giannikos, N | 1 |
| Jaspersen, D | 3 |
| Koerner, T | 1 |
| Schorr, W | 2 |
| Brennenstuhl, M | 2 |
| Raschka, C | 2 |
| Hammar, CH | 2 |
| Della Beffa, V | 1 |
| Carelli-Basile, A | 1 |
| Leli, R | 1 |
| Fontana, D | 1 |
| Lazzaroni, M | 3 |
| Maconi, G | 4 |
| Bargiggia, S | 3 |
| Minguzzi, M | 1 |
| Bianchi Porro, G | 5 |
| Heldwein, W | 2 |
| Klann, H | 2 |
| Simon, T | 2 |
| Schmitt, W | 1 |
| Bate, CM | 3 |
| Booth, SN | 1 |
| Crowe, JP | 2 |
| Mountford, RA | 1 |
| Keeling, PW | 1 |
| Hepworth-Jones, B | 1 |
| Taylor, MD | 2 |
| Richardson, PD | 2 |
| Louw, JA | 4 |
| Lucke, W | 2 |
| Jaskiewicz, K | 2 |
| Lastovica, AJ | 1 |
| Winter, TA | 1 |
| Marks, IN | 5 |
| Michel, P | 1 |
| Duhamel, C | 1 |
| Bazin, B | 1 |
| Raoul, JL | 1 |
| Person, B | 1 |
| Bigard, MA | 1 |
| Legoux, JL | 1 |
| Sallerin, V | 1 |
| Colin, R | 1 |
| Harada, T | 1 |
| Gomollón, F | 1 |
| Bajador, E | 1 |
| Ling, TK | 3 |
| Leung, VK | 1 |
| Li, MK | 1 |
| Cheng, AF | 2 |
| Li, AK | 2 |
| Assouad, M | 1 |
| Vicks, SL | 1 |
| Pokroy, MV | 1 |
| Willcourt, RJ | 1 |
| Kaplan, B | 1 |
| Koppelo, KL | 1 |
| Dominguez, HL | 1 |
| Freston, JW | 3 |
| Pan, S | 1 |
| Liao, CH | 1 |
| Lien, GS | 1 |
| Chen, SH | 1 |
| Archimandritis, A | 2 |
| Balatsos, V | 2 |
| Delis, V | 2 |
| Mentis, A | 1 |
| Kastanas, K | 1 |
| Scandalis, N | 1 |
| Arizón Deza, P | 1 |
| García Tenorio, A | 1 |
| Gonzalo Til, A | 1 |
| Manero Ruiz, I | 1 |
| Mur Lalueza, MJ | 1 |
| Pascual Parrilla, MS | 1 |
| Berndt, H | 1 |
| Dobrilla, G | 2 |
| Di Fede, F | 1 |
| Lee, MG | 1 |
| Rühl, GH | 1 |
| Ohtaki, T | 1 |
| Kudo, M | 2 |
| Kimura, T | 1 |
| Meguro, T | 1 |
| Horita, S | 1 |
| Inoue, K | 1 |
| Hallerbäck, B | 2 |
| Unge, P | 4 |
| Carling, L | 3 |
| Edwin, B | 1 |
| Havu, N | 2 |
| Lyrenäs, E | 1 |
| Lundberg, K | 1 |
| Smith, PM | 2 |
| Kerr, GD | 1 |
| Cockel, R | 1 |
| Ross, BA | 1 |
| Brown, P | 1 |
| Dronfield, MW | 1 |
| Green, JR | 1 |
| Hislop, WS | 1 |
| Theodossi, A | 1 |
| Tytgat, GN | 5 |
| Penston, JG | 1 |
| Karita, M | 1 |
| Morshed, MG | 1 |
| Ouchi, K | 1 |
| Okita, K | 2 |
| Festen, HP | 2 |
| Cellini, L | 1 |
| Allocati, N | 1 |
| Di Campli, E | 1 |
| Dainelli, B | 1 |
| Netchvolodoff, CV | 1 |
| Kihira, K | 1 |
| Kasano, T | 1 |
| Ido, K | 1 |
| Jerome-Zapadka, KM | 1 |
| Clarke, MR | 1 |
| Sekas, G | 1 |
| Dubracić, D | 1 |
| Pulanić, R | 1 |
| Katicić, M | 1 |
| Car, D | 1 |
| Georgijević, A | 1 |
| Cvitanović, B | 1 |
| Busam, J | 1 |
| Garbe, WE | 1 |
| Stålhammar, NO | 2 |
| Dent, J | 4 |
| Mackinnon, M | 2 |
| Reed, W | 1 |
| Narielvala, FM | 2 |
| Hetzel, DJ | 3 |
| Solcia, E | 4 |
| Shearman, DJ | 1 |
| Misra, SC | 1 |
| Dasarathy, S | 1 |
| Sharma, MP | 1 |
| Chen, SP | 1 |
| Bei, L | 1 |
| Wen, SH | 1 |
| Sakaki, N | 2 |
| Hosking, SW | 1 |
| Bell, GD | 2 |
| Powell, KU | 1 |
| Naveau, S | 1 |
| Bour, B | 1 |
| Pariente, EA | 1 |
| Hamelin, B | 1 |
| Garcia, E | 1 |
| Grasso, GA | 1 |
| De Boni, M | 1 |
| Vianello, F | 1 |
| De Bona, M | 1 |
| Pasquino, M | 1 |
| Chiozzini, G | 1 |
| Saggioro, A | 2 |
| Petrin, P | 1 |
| Costantino, V | 1 |
| Canton, A | 1 |
| Rune, SJ | 2 |
| Justesen, T | 1 |
| Hansen, JM | 1 |
| Jensen, TG | 1 |
| Eriksen, J | 2 |
| Thomsen, OO | 1 |
| Scheibel, J | 1 |
| Bonnevie, O | 1 |
| Bremmelgaard, A | 1 |
| Vilien, M | 1 |
| Uemura, N | 1 |
| Okamoto, S | 1 |
| Mukai, T | 1 |
| Yamaguchi, S | 1 |
| Kaji, M | 1 |
| Hrruma, K | 1 |
| Sumii, K | 1 |
| Kajiyama, G | 2 |
| Laursen, LS | 2 |
| Havelund, T | 3 |
| Bondesen, S | 1 |
| Hansen, J | 2 |
| Sanchez, G | 1 |
| Sebelin, E | 1 |
| Fenger, C | 1 |
| Lanas, A | 3 |
| Artal, A | 1 |
| Blás, JM | 1 |
| Arroyo, MT | 1 |
| Lopez-Zaborras, J | 1 |
| Sáinz, R | 2 |
| Fennerty, MB | 1 |
| Robinson, M | 2 |
| Lanza, F | 2 |
| Avner, D | 1 |
| Haber, M | 5 |
| Chua, RT | 1 |
| Wang, K | 1 |
| Lee, CH | 1 |
| Lee, SD | 2 |
| Kadayifci, A | 1 |
| Oksüzöğlu, G | 1 |
| Trespi, E | 1 |
| Perego, M | 2 |
| Alvisi, C | 1 |
| Villani, L | 2 |
| Luinetti, O | 1 |
| Cesana, B | 3 |
| Figueroa, G | 1 |
| Acuña, R | 1 |
| Troncoso, M | 1 |
| Portell, DP | 1 |
| Toledo, MS | 1 |
| Albornoz, V | 1 |
| Vigneaux, J | 1 |
| Bischof, G | 1 |
| Feil, W | 1 |
| Riegler, M | 1 |
| Wenzl, E | 1 |
| Schiessel, R | 1 |
| Jönsson, B | 2 |
| Carlsson, J | 1 |
| Rudbäck, A | 1 |
| Zeijlon, L | 2 |
| Santander, C | 1 |
| Grávalos, RG | 1 |
| Gómez-Cedenilla, A | 1 |
| Cantero, J | 1 |
| Bolle, KH | 1 |
| Bästlein, E | 2 |
| Meining, A | 2 |
| Girdwood, AH | 1 |
| Simjee, AE | 2 |
| Sontag, SJ | 2 |
| Kogut, DG | 1 |
| Campbell, DR | 1 |
| Richter, J | 3 |
| Swarbrick, ET | 1 |
| Gough, AL | 1 |
| Foster, CS | 1 |
| Christian, J | 1 |
| Garrett, AD | 1 |
| Langworthy, CH | 1 |
| Avsar, E | 1 |
| Kalayci, C | 1 |
| Tözün, N | 1 |
| Lawrence, R | 1 |
| Kiziltas, S | 1 |
| Gültekin, O | 1 |
| Ulusoy, NB | 1 |
| Bulgakov, SA | 1 |
| Axon, AT | 3 |
| Tildesley, G | 1 |
| Martin, JL | 1 |
| Lai, JY | 1 |
| De Boer, WA | 1 |
| Driessen, WM | 1 |
| Geuskens, LM | 1 |
| Parente, F | 1 |
| Imbesi, V | 1 |
| Montrone, F | 1 |
| Caruso, I | 1 |
| Sukegawa, M | 1 |
| Katagiri, M | 1 |
| Koshiyama, T | 1 |
| Kagaya, H | 1 |
| Nishikawa, K | 1 |
| Hokari, K | 1 |
| Takeda, H | 1 |
| Schwacha, H | 1 |
| Van Den Boom, G | 1 |
| Go, PM | 1 |
| Hameeteman, W | 1 |
| Dallemagne, B | 1 |
| Ament, AJ | 1 |
| Tsujiai, T | 1 |
| Tamura, K | 1 |
| Goh, KL | 1 |
| Navaratnam, P | 1 |
| Peh, SC | 1 |
| Vreeburg, EM | 1 |
| de Bruijne, HW | 1 |
| Snel, P | 3 |
| Bartelsman, JW | 1 |
| Rauws, EA | 1 |
| O'Moráin, CA | 2 |
| Beattie, AD | 1 |
| Thompson, RP | 2 |
| Hollanders, FD | 1 |
| Baron, JH | 1 |
| Lynch, DA | 1 |
| Dixon, MF | 2 |
| Tompkins, DS | 1 |
| Birrell, H | 1 |
| Gillon, KR | 4 |
| Chan, LY | 1 |
| Hazell, SL | 1 |
| Daskalopoulous, G | 1 |
| Mitchell, HM | 1 |
| Massey, D | 1 |
| Khuroo, MS | 1 |
| Yattoo, GN | 1 |
| Shah, AA | 1 |
| Sodi, JS | 1 |
| Boixeda, D | 2 |
| Martín de Argila, C | 2 |
| Lerang, F | 1 |
| Moum, B | 1 |
| Ragnhildstveit, E | 1 |
| Haug, JB | 1 |
| Hauge, T | 1 |
| Tolås, P | 1 |
| Aubert, E | 1 |
| Henriksen, M | 1 |
| Efskind, PS | 1 |
| Nicolaysen, K | 1 |
| Søberg, T | 1 |
| Odegaard, A | 1 |
| Berge, T | 1 |
| Hatlebakk, JG | 3 |
| Berstad, A | 2 |
| Roufail, W | 1 |
| Hirschowitz, BI | 2 |
| Sabesin, SM | 1 |
| Wu, WC | 1 |
| Behar, J | 1 |
| Peterson, WL | 2 |
| Kranz, KR | 1 |
| Tarnawski, A | 1 |
| Dayal, Y | 3 |
| Berman, R | 1 |
| Simon, TJ | 1 |
| Aalykke, C | 1 |
| Rasmussen, L | 1 |
| Ebell, MH | 1 |
| Warbasse, L | 1 |
| Brenner, C | 1 |
| Harris, RA | 2 |
| Kuppermann, M | 2 |
| Richter, JE | 2 |
| Carlsson, R | 1 |
| Galmiche, JP | 1 |
| Lundell, L | 3 |
| Frison, L | 1 |
| Venables, TL | 1 |
| Newland, RD | 1 |
| Patel, AC | 1 |
| Hole, J | 1 |
| Copeman, MB | 1 |
| Turbitt, ML | 1 |
| Rinaldi, V | 1 |
| Zullo, A | 1 |
| Diana, F | 1 |
| de Francesco, V | 1 |
| Pugliano, F | 1 |
| Attili, AF | 1 |
| Pohle, T | 1 |
| Hilker, E | 1 |
| Domschke, W | 1 |
| Bohmer, CJ | 1 |
| Niezen-de Boer, MC | 1 |
| Klinkenberg-Knol, EC | 7 |
| Tuynman, HA | 1 |
| Voskuil, JH | 1 |
| Devillé, WL | 1 |
| Meuwissen, SG | 6 |
| O'Morain, C | 2 |
| Dettmer, A | 1 |
| Rambow, A | 1 |
| von Fritsch, E | 1 |
| Fraser, AG | 1 |
| Wo, JM | 1 |
| Grist, WJ | 1 |
| Gussack, G | 1 |
| Delgaudio, JM | 1 |
| Waring, JP | 1 |
| Chiocca, JC | 1 |
| Salis, GB | 1 |
| Navarro, JF | 1 |
| Gallego, E | 1 |
| Avilés, J | 1 |
| Graham, DY | 3 |
| Hunt, RH | 1 |
| Lee, FY | 2 |
| Tseng, GY | 2 |
| Goff, J | 1 |
| Silvers, D | 1 |
| Winters, J | 1 |
| Jhala, N | 1 |
| Jennings, D | 1 |
| Greski-Rose, P | 1 |
| Müller, P | 1 |
| Simon, B | 1 |
| Russo, A | 1 |
| Dattilo, M | 1 |
| Nagasawa, Y | 1 |
| Tatsuta, M | 1 |
| Iishi, H | 1 |
| Ishiguro, S | 1 |
| Karrasch, JA | 1 |
| Szczepañski, L | 2 |
| Walker, DG | 1 |
| Barkun, A | 1 |
| Haga, Y | 1 |
| Nakatsura, T | 1 |
| Shibata, Y | 1 |
| Sameshima, H | 1 |
| Nakamura, Y | 1 |
| Tanimura, M | 1 |
| Ogawa, M | 1 |
| Bordi, C | 1 |
| Pilato, FP | 1 |
| Damilano, I | 1 |
| Annibale, B | 2 |
| Cherian, P | 3 |
| Jones, RB | 2 |
| Vaishnavi, A | 2 |
| Manek, S | 1 |
| Bishop, A | 2 |
| Polak, J | 2 |
| Brooks, A | 2 |
| Morris, P | 3 |
| Thompson, M | 3 |
| D'Silva, J | 2 |
| Parkin, S | 1 |
| Patterson, J | 2 |
| King, VJ | 1 |
| Lindsetmo, RO | 1 |
| Johnsen, R | 1 |
| Revhaug, A | 1 |
| Carnicer, J | 1 |
| Kovacs, TO | 2 |
| Campbell, D | 2 |
| Rose, P | 3 |
| Jennings, DE | 2 |
| Konar, A | 1 |
| Das, AS | 1 |
| De, PK | 1 |
| Roy, A | 1 |
| Mazumder, DN | 1 |
| Schwartz, H | 1 |
| Krause, R | 1 |
| Sahba, B | 1 |
| Weissfeld, A | 1 |
| Siepman, N | 1 |
| Freston, J | 1 |
| Nobre-Leitão, C | 1 |
| Lage, P | 1 |
| Cravo, M | 1 |
| Cabeçadas, J | 1 |
| Chaves, P | 1 |
| Alberto-Santos, A | 1 |
| Correia, J | 1 |
| Soares, J | 1 |
| Costa-Mira, F | 1 |
| Macri, G | 1 |
| Milani, S | 1 |
| Surrenti, E | 1 |
| Passaleva, MT | 1 |
| Salvadori, G | 1 |
| Surrenti, C | 1 |
| Guslandi, M | 1 |
| Améndola, R | 1 |
| Roldán, CD | 1 |
| Morgade, L | 1 |
| Solagna, A | 1 |
| Lineado, A | 1 |
| Musi, AO | 1 |
| Valero, J | 1 |
| Zerbo, O | 1 |
| Kogan, Z | 1 |
| Ferro, FE | 1 |
| Schenone, L | 1 |
| Corti, R | 1 |
| Cook, DJ | 1 |
| Filipowicz-Sosnowska, A | 1 |
| Wason, CM | 1 |
| Landray, MJ | 1 |
| Ringrose, T | 1 |
| Ferner, RE | 1 |
| Arnold, IR | 1 |
| Wason, C | 1 |
| Langman, MJ | 1 |
| Peny, MO | 1 |
| Delhaye, M | 1 |
| Suzuki, J | 1 |
| Kobayasi, I | 1 |
| Fujita, T | 1 |
| Zhang, T | 1 |
| O'Keefe, SJ | 1 |
| Winter, T | 2 |
| Ogden, J | 1 |
| Calvet, X | 1 |
| Campo, R | 1 |
| Brullet, E | 1 |
| Rué, M | 1 |
| Strauss, RS | 1 |
| Calenda, KA | 1 |
| Mobassaleh, M | 1 |
| Sekine, H | 1 |
| Ohara, S | 1 |
| Iijima, K | 1 |
| Kato, K | 1 |
| Nakagawa, M | 1 |
| Ooishi, M | 1 |
| Yoda, Y | 1 |
| Kawamura, N | 1 |
| Ooizumi, H | 1 |
| Saitou, M | 1 |
| Nakagawa, S | 1 |
| Harase, I | 1 |
| Okuda, J | 1 |
| Ida, K | 1 |
| Epling, J | 1 |
| Taylor, H | 1 |
| García-Romero, E | 1 |
| del Val, A | 1 |
| Garrigues, V | 1 |
| Cuquerella, J | 1 |
| Higón, MD | 1 |
| Barrachina, M | 1 |
| Pons, V | 1 |
| Bixquert, M | 1 |
| Ponce, J | 1 |
| Badia, X | 1 |
| Segú, JL | 1 |
| Ollé, A | 1 |
| Brosa, M | 1 |
| García Ponte, L | 1 |
| Schenk, E | 1 |
| Tan, G | 1 |
| Nelis, F | 3 |
| Manika, Z | 1 |
| Skandalis, N | 1 |
| Diete, U | 1 |
| Gil, J | 1 |
| Misiuna, P | 1 |
| Spiller, RC | 1 |
| Stasiewicz, J | 1 |
| Treichel, H | 1 |
| Ujszászy, L | 1 |
| Zanten, SJ | 1 |
| Crowe, J | 1 |
| Trewby, PN | 1 |
| Keeling, PN | 1 |
| Weir, D | 1 |
| Crouch, SL | 1 |
| Pap, A | 1 |
| Kordecki, H | 1 |
| Schmid, V | 1 |
| Ohlsson, L | 1 |
| Wahlqvist, P | 1 |
| Wiklund, I | 1 |
| Honiball, PJ | 1 |
| Van Zyl, JH | 1 |
| Grundling, HD | 1 |
| Eloff, FP | 1 |
| Spies, SK | 1 |
| Fischer, R | 2 |
| Fischer, DR | 1 |
| Nussbaum, MS | 1 |
| Pritts, TA | 1 |
| Gilinsky, NH | 1 |
| Weesner, RE | 1 |
| Martin, SP | 1 |
| Giannella, RA | 1 |
| Chen, SY | 1 |
| Wang, JY | 1 |
| Chen, J | 1 |
| Zhang, XD | 1 |
| Zhang, SS | 1 |
| Hsieh, YH | 1 |
| Chang, FY | 1 |
| Kuipers, EJ | 1 |
| Schenk, BE | 1 |
| Mach, T | 1 |
| Zahradnik-Bilska, J | 1 |
| Martino, G | 1 |
| Paoletti, M | 1 |
| Marcheggiano, A | 1 |
| D'Ambra, G | 1 |
| Delle Fave, G | 1 |
| Sou, Y | 1 |
| Saita, H | 1 |
| Takahashi, Y | 1 |
| Yoshinaga, T | 1 |
| Matsukawa, Y | 1 |
| Sekikawa, A | 1 |
| Nakazawa, T | 1 |
| Shio, S | 1 |
| Kohigashi, K | 1 |
| Bustamante, M | 1 |
| Stollman, N | 1 |
| Rollan, A | 1 |
| Giancaspero, R | 1 |
| Fuster, F | 1 |
| Acevedo, C | 1 |
| Figueroa, C | 1 |
| Hola, K | 1 |
| Schulz, M | 1 |
| Duarte, I | 1 |
| Lam, YH | 1 |
| Chan, AC | 1 |
| Lee, DW | 1 |
| Law, BK | 1 |
| Lau, WY | 2 |
| de Mestier, P | 1 |
| Romero, Y | 1 |
| Egan, LJ | 1 |
| Murray, JA | 1 |
| Tassios, PS | 1 |
| Raptis, SA | 1 |
| Remacha, B | 1 |
| Katz, PO | 1 |
| Castell, DO | 1 |
| Shamaly, H | 1 |
| Berkowitz, D | 1 |
| Rosenthal, E | 1 |
| Naveh, Y | 1 |
| Beker, JA | 1 |
| Dekkers, C | 1 |
| Bjaaland, T | 1 |
| Finnegan, V | 1 |
| Capurso, L | 1 |
| Furuta, T | 1 |
| Takashima, M | 1 |
| Shirai, N | 1 |
| Xiao, F | 1 |
| Hanai, H | 1 |
| Ohashi, K | 1 |
| Ishizaki, T | 1 |
| de Lima Pontes, PA | 1 |
| De Biase, NG | 1 |
| Gadelha, EC | 1 |
| Pace, F | 2 |
| Battaglia, F | 1 |
| Dal Bò, N | 1 |
| Benedetti, E | 1 |
| Bottona, E | 1 |
| Caroli, A | 1 |
| Costan-Biedo, F | 1 |
| De Bastiani, R | 1 |
| Germanà, B | 1 |
| Andrea Grassi, S | 1 |
| Madia, D | 1 |
| Marcon, V | 1 |
| Marin, R | 1 |
| Monica, F | 1 |
| Olivieri, P | 1 |
| Orzes, N | 1 |
| Ronzani, G | 1 |
| Tafner, G | 1 |
| Arnold, R | 2 |
| Fischer, M | 1 |
| Koelz, HR | 1 |
| Bermejo, F | 1 |
| Defarges, V | 1 |
| Sanz, JM | 1 |
| García Plaza, A | 1 |
| Brun, J | 1 |
| Sörngård, H | 1 |
| Frank, F | 1 |
| Stricker, T | 1 |
| Stallmach, T | 1 |
| Braegger, CP | 1 |
| Kaneko, E | 1 |
| Hoshihara, Y | 1 |
| Harasawa, S | 1 |
| Ashida, K | 1 |
| Kobayashi, K | 1 |
| Ogawa, N | 1 |
| Yao, T | 1 |
| Muto, Y | 1 |
| Nakazawa, S | 1 |
| Caos, A | 1 |
| Moskovitz, M | 1 |
| Perdomo, C | 1 |
| Niecestro, R | 1 |
| Barth, J | 1 |
| Carta, M | 1 |
| Dore, MP | 1 |
| Idda, M | 1 |
| Casu, M | 1 |
| Realdi, G | 1 |
| Scheurlen, M | 1 |
| Hizawa, K | 1 |
| Nakahara, T | 1 |
| Yano, Y | 1 |
| Inuzuka, S | 1 |
| Akagi, K | 1 |
| Adamsson, I | 1 |
| Edlund, C | 1 |
| Seensalu, R | 1 |
| Engstrand, L | 1 |
| Nehme, O | 1 |
| Barkin, JS | 1 |
| Khor, CJ | 1 |
| Fock, KM | 1 |
| Ng, TM | 1 |
| Teo, EK | 1 |
| Sim, CS | 1 |
| Tan, AL | 1 |
| Ng, A | 1 |
| Buderus, S | 1 |
| Keller, KM | 1 |
| Lentze, MJ | 1 |
| Pashankar, D | 1 |
| Blair, GK | 1 |
| Israel, DM | 1 |
| Della Libera, E | 1 |
| Rohr, MR | 1 |
| Moraes, M | 1 |
| Siqueira, ES | 1 |
| Ferrari, AP | 1 |
| Luzza, F | 1 |
| Giglio, A | 1 |
| Ciliberto, E | 1 |
| Belmonte, A | 1 |
| Cavaliere, C | 1 |
| Saccà, N | 1 |
| Frandina, C | 1 |
| Trimboli, V | 1 |
| Pallone, F | 1 |
| Schwizer, W | 1 |
| Thumshirn, M | 1 |
| Guldenschuh, I | 1 |
| Menne, D | 1 |
| Cathomas, G | 1 |
| Fried, M | 1 |
| Meijer, K | 1 |
| Peters, FT | 1 |
| van der Meer, J | 1 |
| Bishop, AE | 1 |
| Polak, JM | 1 |
| Romanska, H | 1 |
| Perry, MJ | 1 |
| Rowland, A | 1 |
| Schneider, A | 1 |
| Ng, W | 1 |
| McCaldin, B | 1 |
| Perri, F | 1 |
| Villani, MR | 1 |
| Quitadamo, M | 1 |
| Annese, V | 1 |
| Niro, GA | 1 |
| Andriulli, A | 1 |
| Nagahara, A | 2 |
| Miwa, H | 2 |
| Ohkura, R | 1 |
| Yamada, T | 1 |
| Sato, K | 1 |
| Hojo, M | 2 |
| Savides, TJ | 1 |
| Pratha, V | 1 |
| Oncel, M | 1 |
| Kurt, N | 1 |
| Walsh, M | 1 |
| Avcu, N | 1 |
| Avcu, F | 1 |
| Beyan, C | 1 |
| Ural, AU | 1 |
| Kaptan , K | 1 |
| Ozyurt, M | 1 |
| Nevruz, O | 1 |
| Yalçin, A | 1 |
| Plein, K | 1 |
| Madisch, A | 1 |
| Hotz, J | 2 |
| Hawkey, GM | 1 |
| Cole, AT | 1 |
| McIntyre, AS | 1 |
| Long, RG | 1 |
| Sazhin, VP | 1 |
| Fedorov, AV | 1 |
| Masoodi, I | 1 |
| Chey, WD | 1 |
| Hildebrand, P | 1 |
| Bardhan, P | 1 |
| Rossi, L | 1 |
| Parvin, S | 1 |
| Rahman, A | 1 |
| Arefin, MS | 1 |
| Hasan, M | 1 |
| Ahmad, MM | 1 |
| Glatz-Krieger, K | 1 |
| Terracciano, L | 1 |
| Bauerfeind, P | 1 |
| Beglinger, C | 1 |
| Gyr, N | 1 |
| Khan, AK | 1 |
| Moayyedi, P | 1 |
| Bardhan, C | 1 |
| Young, L | 1 |
| Brown, L | 1 |
| Keto, Y | 2 |
| Ebata, M | 2 |
| Okabe, S | 2 |
| Loginov, AS | 1 |
| Reshetnyak, VI | 1 |
| Dudik, TV | 1 |
| Vostroknutova, GN | 1 |
| Il'chenko, AA | 1 |
| Kaprel'yants, AS | 1 |
| Sharma, VK | 1 |
| Sahai, AV | 1 |
| Corder, FA | 1 |
| Howden, CW | 2 |
| Tang, SJ | 1 |
| Nieto, JM | 1 |
| Ohning, GV | 1 |
| Tsimmerman, IaS | 1 |
| Shchetkin, DI | 1 |
| Kim, JS | 1 |
| Kim, SG | 1 |
| Choi, IJ | 1 |
| Park, MJ | 1 |
| Kim, BG | 1 |
| Jung, HC | 1 |
| Song, IS | 1 |
| Tomita, K | 1 |
| Jackson, RL | 1 |
| Knippig, C | 1 |
| Arand, F | 1 |
| Leodolter, A | 1 |
| Nilius, M | 1 |
| Klein, U | 1 |
| Bleau, BL | 1 |
| Gostout, CJ | 1 |
| Sherman, KE | 1 |
| Shaw, MJ | 1 |
| Harford, WV | 1 |
| Keate, RF | 1 |
| Bracy, WP | 1 |
| Fleischer, DE | 1 |
| Lau, GK | 1 |
| Yuen, MF | 1 |
| Lai, CL | 2 |
| Sugiyama, M | 1 |
| Katamura, H | 1 |
| Yanai, H | 1 |
| Tada, M | 1 |
| Inamoto, Y | 1 |
| Tsukamoto, Y | 1 |
| Niwa, Y | 1 |
| Arisawa, T | 1 |
| Rune, S | 1 |
| Zak, J | 2 |
| Le Roux, E | 1 |
| Lastovica, A | 1 |
| Anker Hansen, OJ | 1 |
| de Groot, GH | 1 |
| Geldof, H | 1 |
| Efskind, P | 1 |
| Elsborg, L | 1 |
| Karvonen, AL | 1 |
| Ohlin, B | 1 |
| Kleinert, R | 1 |
| Grymbowski, T | 1 |
| Hennig, U | 1 |
| Schwarz, JA | 1 |
| Feliciano, DV | 1 |
| Colon-Pagan, J | 1 |
| Morse, RS | 1 |
| Johnson, TL | 1 |
| Walsh, JH | 1 |
| McCullough, AJ | 1 |
| Marks, JW | 1 |
| Sklar, M | 1 |
| Stone, RC | 1 |
| Cagliola, AJ | 1 |
| Kaye, GL | 1 |
| McCormick, PA | 1 |
| Siringo, S | 1 |
| Hobbs, KE | 1 |
| McIntyre, N | 1 |
| Burroughs, AK | 1 |
| Deruyter, L | 1 |
| Van Blerk, M | 1 |
| Cadière, GB | 1 |
| De Graef, J | 1 |
| Willems, G | 1 |
| Backman, L | 1 |
| Ekström, P | 1 |
| Enander, LK | 1 |
| Falkmer, S | 1 |
| Fausa, O | 1 |
| Grimelius, L | 1 |
| Lönroth, H | 1 |
| Gyenes, E | 1 |
| Johnston, DA | 1 |
| Young, GO | 1 |
| Tigler-Wybrandi, NA | 1 |
| Bridger, S | 1 |
| Bianchi-Porro, G | 1 |
| Sangaletti, O | 1 |
| Peracchia, A | 1 |
| Bonavina, L | 1 |
| Holt, S | 1 |
| Wingate, DL | 1 |
| Marciano-D'Amore, DA | 1 |
| Paterson, WG | 1 |
| Da Costa, LR | 1 |
| Beck, IT | 1 |
| Jansen, JB | 2 |
| Lamers, CB | 3 |
| Andersen, BN | 1 |
| Rehfeld, JF | 1 |
| Kjaergaard, J | 1 |
| Rask-Madsen, J | 2 |
| Martinson, J | 1 |
| Solhaug, JH | 1 |
| Engström, G | 1 |
| Chosidow, O | 2 |
| Joly, P | 2 |
| Laurent-Puig, P | 1 |
| Prost, C | 1 |
| Espagne, E | 1 |
| Wechsler, J | 1 |
| Roujeau, JC | 2 |
| Revuz, J | 2 |
| Walan, A | 2 |
| Laurent-Poig, P | 1 |
| Delchier, JC | 1 |
| Bethke, B | 1 |
| Zentilin, P | 1 |
| Celle, G | 1 |
| Branicki, FJ | 1 |
| Lok, AS | 1 |
| Ng, MM | 1 |
| Poon, GP | 1 |
| Bader, JP | 1 |
| Classen, M | 1 |
| Piper, DW | 1 |
| Rutgersson, K | 1 |
| Eriksson, S | 1 |
| Farup, PG | 1 |
| Rosseland, AR | 1 |
| Halvorsen, L | 1 |
| Andersen, OK | 1 |
| Bernklev, T | 1 |
| Walt, RP | 1 |
| Daneshmend, TK | 1 |
| Reed, WD | 1 |
| McCarthy, JH | 1 |
| Mitchell, B | 1 |
| Beveridge, BR | 1 |
| Laurence, BH | 1 |
| Gibson, GG | 1 |
| Depla, AC | 1 |
| Bartelsman, JF | 1 |
| Roos, CM | 1 |
| Jansen, HM | 1 |
| Kelbaek, H | 1 |
| Jensen, KG | 1 |
| Bendtsen, F | 1 |
| Linde, J | 1 |
| Højlund, M | 1 |
| Andersen, HH | 1 |
| Deveney, CW | 1 |
| Deveney, KE | 1 |
| Spiro, HM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reinfection After Eradication of Helicobacter Pylori Infection in Adult :A National Multicentre Study[NCT02674802] | 3,500 participants (Anticipated) | Observational | 2015-12-31 | Recruiting | |||
| A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Under[NCT00251979] | Phase 3 | 1,312 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial[NCT04039412] | Phase 4 | 330 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| A Randomized, Controlled Trial of Ligation Plus Vasoconstrictor vs.Ligation Plus Proton Pump Inhibitor in the Control of Acute Esophageal Variceal Bleeding[NCT01112852] | Phase 4 | 118 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Comparative Effectiveness Research: Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails to Treat the Patients With Acute Variceal Bleeding[NCT02311608] | 1,320 participants (Anticipated) | Observational | 2014-02-28 | Recruiting | |||
| Comparison of High Dose Infusion and Low Dose Bolus Intravenous Omeprazole for Treatment of Bleeding Ulcer With Adherent Clot[NCT02536989] | Phase 4 | 40 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Randomized, Placebo-Controlled Assessment of Lansoprazole 30 mg Bid in the Treatment of Gastroesophageal Reflux Associated With Laryngitis[NCT00369265] | Phase 4 | 18 participants (Actual) | Interventional | 2006-08-31 | Terminated (stopped due to Pharmaceutical company purchased by another company and funding was terminated.) | ||
| European Registry on the Management of Helicobacter Pylori Infection[NCT02328131] | 10,000 participants (Anticipated) | Observational | 2013-06-30 | Recruiting | |||
| Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding[NCT00687336] | Phase 4 | 178 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | ||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis[NCT01524757] | 48 participants (Anticipated) | Interventional | 2012-03-31 | Not yet recruiting | |||
| A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)[NCT02755753] | Phase 4 | 143 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Capsaicin-sensitive Transient Receptor Potential Vanilloid One (TRPV1) and Tyrosine Kinase (TrkA) Receptor Expression in Children With Retrosternal Pain[NCT00677378] | 77 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study[NCT02081404] | 98 participants (Actual) | Interventional | 2009-03-01 | Completed | |||
| Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori[NCT00149084] | Phase 3 | 296 participants | Interventional | 2003-04-30 | Recruiting | ||
| A Randomized Controlled Trial Comparing Proton Pump Inhibitor Therapy With and Without Interarytenoid Botulinum Toxin Injection for Vocal Fold Granuloma[NCT01678053] | Phase 2 | 0 participants (Actual) | Interventional | 2012-09-30 | Withdrawn (stopped due to Was not able to recruit patients for randomization.) | ||
| A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment[NCT02978157] | 102 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage: A Double-Blind, Randomized, Placebo-Controlled Trial[NCT02903017] | Phase 4 | 114 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00251979)
Timeframe: Within 30 days
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 29 |
| Placebo | 53 |
(NCT00251979)
Timeframe: Within 7 days
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 27 |
| Placebo | 50 |
(NCT00251979)
Timeframe: Within 72 hours
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 22 |
| Placebo | 40 |
(NCT00251979)
Timeframe: Within 30 days
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 2 |
| Placebo | 3 |
(NCT00251979)
Timeframe: Within 30 days
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 3 |
| Placebo | 8 |
(NCT00251979)
Timeframe: Within 72 hours
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 1 |
| Placebo | 0 |
(NCT00251979)
Timeframe: within 30 days
| Intervention | blood units (Number) |
|---|---|
| Esomeprazole | 589 |
| Placebo | 935 |
(NCT00251979)
Timeframe: Within 72 hours
| Intervention | blood units (Number) |
|---|---|
| Esomeprazole | 492 |
| Placebo | 738 |
(NCT00251979)
Timeframe: Within 30 days
| Intervention | days (Number) |
|---|---|
| Esomeprazole | 284 |
| Placebo | 500 |
(NCT00251979)
Timeframe: Within 30 days
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 24 |
| Placebo | 45 |
(NCT00251979)
Timeframe: Within 72 hours
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 16 |
| Placebo | 32 |
(NCT00251979)
Timeframe: Within 30 days
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 10 |
| Placebo | 21 |
(NCT00251979)
Timeframe: Within 72 hours
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 5 |
| Placebo | 9 |
Questionnaire to measure the number of Participants with Treatment-Emergent Adverse Events (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 49 |
| (2) Hybrid Regimen | 58 |
| (3) Levofloxacin Quadruple Regimen | 44 |
Measuring the curative rate of each regimen by a fecal antigen test (NCT04039412)
Timeframe: 40-44 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 102 |
| (2) Hybrid Regimen | 101 |
| (3) Levofloxacin Quadruple Regimen | 91 |
Questionnaire to evaluate the compliance with each treatment regimen (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 109 |
| (2) Hybrid Regimen | 107 |
| (3) Levofloxacin Quadruple Regimen | 108 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
Number of participants with negative H pylori status in follow-up tests as a measure of successful eradication (NCT02978157)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo | 36 |
| Esomeprazole+Bismuth+Tetra+Levo | 49 |
47 reviews available for omeprazole and Recrudescence
| Article | Year |
|---|---|
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Dr | 2010 |
[Dilemma between gastroprotection and cardiovascular prevention].
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; | 2010 |
Treating patients with acute gastrointestinal bleeding or rebleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials a | 2003 |
Review article: the role of antisecretory therapy in the management of non-variceal upper gastrointestinal bleeding.
Topics: Administration, Oral; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Gastrointestinal Hemorrhage; H | 2005 |
[Quality of ulcer healing and rebamipide].
Topics: Alanine; Amoxicillin; Animals; Anti-Ulcer Agents; Antioxidants; Cytokines; Drug Therapy, Combination | 2005 |
[Modern attitude towards management of laryngopharyngeal form of gastroesophageal reflux disease. Lithuanian clinical practice guidelines for adults].
Topics: Adult; Algorithms; Antacids; Anti-Ulcer Agents; Domperidone; Dopamine Antagonists; Gastroesophageal | 2007 |
Medical management of peptic ulcer.
Topics: Aluminum; Antacids; Benzimidazoles; Bismuth; Carbenoxolone; Cimetidine; Duodenal Ulcer; Humans; Omep | 1984 |
[Conservative therapy of peptic ulcer].
Topics: Ampicillin; Gastric Acidity Determination; Helicobacter pylori; Histamine H2 Antagonists; Humans; Om | 1995 |
[New therapy of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alprostadil; Anti-Ulcer Agents; Histamine H2 Antagonists; H | 1995 |
The treatment of gastroesophageal reflux disease.
Topics: Antacids; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole; Recurrence; Sucralf | 1994 |
[Controversies and trends in ulcer therapy. 2: Prevention of recurrence].
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylor | 1993 |
Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Esophagitis; Gastric Acid; Gastr | 1993 |
Gastro-oesophageal reflux.
Topics: Combined Modality Therapy; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole; Re | 1994 |
Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence.
Topics: Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infecti | 1994 |
Review article: Helicobacter pylori eradication--understandable caution but no excuse for inertia.
Topics: Anti-Bacterial Agents; Attitude of Health Personnel; Clinical Trials as Topic; Drug Administration S | 1994 |
Refractory peptic lesions. Therapeutic strategies for ulcers and reflux esophagitis that resist standard regimens.
Topics: Anti-Ulcer Agents; Chronic Disease; Clinical Protocols; Combined Modality Therapy; Drug Therapy, Com | 1993 |
Recurrent upper esophageal webs in association with heterotopic gastric mucosa: case report and literature review.
Topics: Aged; Barrett Esophagus; Deglutition Disorders; Esophagoscopy; Esophagus; Female; Follow-Up Studies; | 1994 |
[Current therapy of Helicobacter pylori infection].
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Helicobacter Infe | 1994 |
Eradication of Helicobacter pylori and its effect in peptic ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Campylobacter Infections; Drug Therapy, Combination; Hu | 1993 |
Helicobacter pylori eradication: the best long-term prophylaxis for ulcer bleeding recurrence?
Topics: Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; | 1995 |
[Losek (omeprazole), a new therapeutic agent in the treatment of peptic ulcer and hyperacidity states].
Topics: Animals; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Acid; Humans; Omeprazole; Peptic Ulcer; Rats; Re | 1995 |
[What is the current therapeutic role of omeprazole in gastroduodenal ulcer disease?].
Topics: Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; | 1997 |
Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis; Esophagosco | 1997 |
Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Lans | 1997 |
[Gastroesophageal reflux disease refractory to medical treatment. Which approach: the pill or the scalpel?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Fundoplication; Gastroesophageal Reflux; Hu | 1997 |
Antisecretory therapy for bleeding peptic ulcer.
Topics: Anti-Ulcer Agents; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Omeprazole; Peptic | 1998 |
[Effect of the eradication of Helicobacter pylori on peptic ulcer healing].
Topics: Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Histological Te | 1999 |
The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Humans; | 2000 |
Medical therapy. Management of the refractory patient.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Therapy, Combination; Enzyme Inhibitors; Gastroesophag | 1999 |
[Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2000 |
Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Topics: Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome | 2000 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Review article: long-term use of proton pump inhibitors in GORD--help or hindrance?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Lansopr | 2001 |
[Pharmacological study on the pathological changes of the gastric mucosa in Helicobacter pylori-infected Mongolian gerbils].
Topics: Adenocarcinoma; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer | 2001 |
Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infection | 2001 |
Lansoprazole for maintenance of remission of erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Esophagitis; H | 2002 |
Clinical significance of hypergastrinaemia: relevance to gastrin monitoring during omeprazole therapy.
Topics: Colonic Neoplasms; Drug Monitoring; Fasting; Gastric Mucosa; Gastrins; Humans; Omeprazole; Ranitidin | 1992 |
Helicobacter pylori, peptic ulcer disease and inhibition of gastric acid secretion.
Topics: Amoxicillin; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Gastric Acid; Gast | 1992 |
Controlled clinical trials of omeprazole in the long-term management of reflux disease.
Topics: Administration, Oral; Australia; Belgium; Biopsy; Double-Blind Method; Endoscopy, Gastrointestinal; | 1992 |
Do perforated duodenal ulcers need an acid-decreasing surgical procedure now that omeprazole is available?
Topics: Duodenal Ulcer; Humans; Omentum; Omeprazole; Peptic Ulcer Perforation; Pylorus; Recurrence; Vagotomy | 1992 |
The role of omeprazole in healing and prevention of reflux disease.
Topics: Esophagitis, Peptic; Gastric Acid; Gastroesophageal Reflux; Humans; Omeprazole; Recurrence; Time Fac | 1992 |
Acid suppression as treatment for NSAID-related peptic ulcers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Gastric Acid; Humans; Omeprazole; Peptic Ulcer; Ranitidine; | 1991 |
Treatment of acid-related disorders with gastric acid inhibitors: the state of the art.
Topics: Gastric Acid; Histamine H2 Antagonists; Humans; Meta-Analysis as Topic; Omeprazole; Peptic Ulcer; Re | 1990 |
Clinical development programme for omeprazole.
Topics: Drug Administration Schedule; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Peptic Ulcer He | 1990 |
Use of omeprazole in the management of reflux oesophagitis resistant to H2-receptor antagonists.
Topics: Esophagitis, Peptic; Gastric Acid; Histamine H2 Antagonists; Humans; Multicenter Studies as Topic; O | 1989 |
Treatment of reflux oesophagitis resistant to H2-receptor antagonists.
Topics: Drug Administration Schedule; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Omeprazole; Rec | 1989 |
Medical treatment of peptic ulcers.
Topics: Aluminum; Antacids; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Cimetidine; Humans; Omeprazole; Para | 1985 |
188 trials available for omeprazole and Recrudescence
| Article | Year |
|---|---|
[Effect of different course of omeprazole in the treatment of laryngopharyngeal reflux].
Topics: Capsules; Humans; Laryngopharyngeal Reflux; Omeprazole; Pepsin A; Proton Pump Inhibitors; Recurrence | 2018 |
Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Dr | 2008 |
Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Administration Sc | 2009 |
Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Drug Administratio | 2009 |
[Effect of yiqi huoxue formula on healing quality and recurrence rate of peptic ulcer].
Topics: Adult; Anti-Ulcer Agents; Drugs, Chinese Herbal; Female; Fibroblast Growth Factor 2; Humans; Male; M | 2009 |
Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse.
Topics: Adult; Aged; Dyspepsia; Endoscopy, Gastrointestinal; Female; Heart Neoplasms; Humans; Male; Middle A | 2010 |
Role of intravenous omeprazole on non-variceal upper gastrointestinal bleeding after endoscopic treatment: a comparative study.
Topics: Antacids; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Female; Gastrointestinal Hemorrhage; Hista | 2010 |
Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey.
Topics: Adult; Aged; Angina Pectoris; Anti-Ulcer Agents; Coronary Angiography; Coronary Artery Disease; Cros | 2011 |
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2011 |
Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Combined Modality Therapy; Esophageal and Gast | 2013 |
Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Combined Modality Therapy; Esophageal and Gast | 2013 |
Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Combined Modality Therapy; Esophageal and Gast | 2013 |
Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Combined Modality Therapy; Esophageal and Gast | 2013 |
Comparison of oral omeprazole and endoscopic ethanol injection therapy for prevention of recurrent bleeding from peptic ulcers with nonbleeding visible vessels or fresh adherent clots.
Topics: Administration, Oral; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Ethanol; Female; Gastrointesti | 2002 |
Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure.
Topics: Adenocarcinoma; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; | 2002 |
Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression.
Topics: Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Esophagoscopy; Female; Follow-Up Studies; Humans; | 2002 |
Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aluminum Hydroxide; Anti-Ulcer Agents; Benzimi | 2003 |
A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Respon | 2003 |
Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment.
Topics: Adult; Anti-Ulcer Agents; Dyspepsia; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; H | 2003 |
Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Metho | 2003 |
Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cross-Over | 2003 |
Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Health Status; Heartburn; He | 2003 |
The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots: a randomized comparison.
Topics: Anti-Ulcer Agents; Combined Modality Therapy; Endoscopy, Gastrointestinal; Female; Follow-Up Studies | 2003 |
Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Clavulanic Acids; Double-Blin | 2003 |
Empiric treatment with high and standard dose of omeprazole in general practice: two-week randomized placebo-controlled trial and 12-month follow-up of health-care consumption.
Topics: Adult; Aged; Delivery of Health Care; Denmark; Dose-Response Relationship, Drug; Drug Administration | 2004 |
[Long-term therapeutic effect of triple therapy consisted of omeperazole, clarithromycin and amoxycillin in children with Helicobacter pylori infection and approach to re-treatment after failure of the treatment].
Topics: Adolescent; Amoxicillin; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, C | 2004 |
Total family unit Helicobacter pylori eradication and pediatric re-infection rates.
Topics: Adolescent; Amoxicillin; Breath Tests; Child; Child, Preschool; Clarithromycin; Community-Acquired I | 2004 |
Dual vs. triple therapy for childhood Helicobacter pylori gastritis: a double-blind randomized multicentre trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Breath Tests; Child; Double-Blind | 2004 |
Symptomatic response to Helicobacter pylori eradication in children with recurrent abdominal pain: double blind randomized placebo-controlled trial.
Topics: Abdominal Pain; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Double | 2004 |
[Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study].
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; H | 2004 |
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Topics: Adult; Aged; Arthritis; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dyspe | 2004 |
Long-term effects of eradication of Helicobacter pylori on relapse and histology in gastric ulcer patients: a two-year follow-up study.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Endoscopy, | 2004 |
Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes.
Topics: Acute Disease; Amoxicillin; Antigens, CD; Coronary Disease; Female; Helicobacter Infections; Helicob | 2004 |
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2005 |
Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2005 |
Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Drug Administrat | 2005 |
Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis.
Topics: Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Esophagitis | 2005 |
Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anthropometry; Anti-Ulcer Agents; | 2005 |
Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibit | 2005 |
The results of Helicobacter pylori eradication on repeated bleeding in patients with stomach ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Administration Sc | 2005 |
Long-term acid suppressive therapy may prevent the relapse of lower esophageal (Schatzki's) rings: a prospective, randomized, placebo-controlled study.
Topics: Anti-Ulcer Agents; Dilatation; Esophageal Diseases; Female; Gastroesophageal Reflux; Humans; Hydroge | 2005 |
Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Inhalation; Adrenal Cortex Hormones; Adult; | 2005 |
Long-term follow-up after eradication of Helicobacter pylori with omeprazole, clarithromycin, and tinidazole (OCT regimen) in a Japanese population.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combina | 2005 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2005 |
Role of intravenous omeprazole in patients with high-risk peptic ulcer bleeding after successful endoscopic epinephrine injection: a prospective randomized comparative trial.
Topics: Adult; Aged; Anti-Ulcer Agents; Blood Transfusion; Cimetidine; Drug Administration Schedule; Electro | 2006 |
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Dose-Re | 2005 |
Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2007 |
A head to head comparison of oral vs intravenous omeprazole for patients with bleeding peptic ulcers with a clean base, flat spots and adherent clots.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Blood Transfusi | 2006 |
Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?
Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Esophagitis, Peptic; Female; Gastroesophagea | 2007 |
Single-session, graded esophageal dilation without fluoroscopy in outpatients with lower esophageal (Schatzki's) rings: a prospective, long-term follow-up study.
Topics: Aged; Ambulatory Care; Deglutition Disorders; Dilatation; Enzyme Inhibitors; Esophageal Stenosis; Es | 2007 |
Omeprazole in duodenal ulceration: acid inhibition, symptom relief, endoscopic healing, and recurrence. Cooperative study.
Topics: Adult; Aged; Alcohol Drinking; Anti-Ulcer Agents; Benzimidazoles; Depression, Chemical; Duodenal Ulc | 1984 |
Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Female; | 1995 |
A comparison of five maintenance therapies for reflux esophagitis.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Disease-Free Survival; Drug Therapy, Combination; Esophagitis, | 1995 |
[Comparison of 2 treatment schemes to eradicate Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Dyspepsia; Endosco | 1995 |
Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 1995 |
Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Amoxicillin; Anti-Bacterial Agents; Anti- | 1995 |
Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Atrophy; Duodenal Ulcer; Gastric Mucosa; | 1995 |
Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full-dose or everyday half-dose administration?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Administration Schedule; Duo | 1995 |
The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antibodi | 1995 |
Effect of lansoprazole on peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobacter Inf | 1995 |
[Long-term cyclic and periodic omeprazole in the prevention of recurrences of duodenal ulcer].
Topics: Adult; Drug Administration Schedule; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omeprazole; | 1995 |
Role of omeprazole in prevention and treatment of postendoscopic variceal sclerotherapy esophageal complications. Double-blind randomized study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Esophageal and Gastric Varices; Eso | 1995 |
Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Drug Admini | 1995 |
Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies.
Topics: Adult; Aged; Cisapride; Drug Administration Schedule; Drug Therapy, Combination; Esophagitis, Peptic | 1995 |
Six months of omeprazole 20 mg daily, 20 mg every other day or 40 mg at weekends in duodenal ulcer patients: a multicenter, prospective, comparative study. Interdisciplinary Group for Ulcer Study.
Topics: Drug Administration Schedule; Duodenal Ulcer; Female; Follow-Up Studies; Humans; Male; Middle Aged; | 1995 |
Two-year follow-up of duodenal ulcer patients treated with omeprazole and amoxicillin.
Topics: Amoxicillin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow | 1995 |
[Clinical significance of clearing Helicobacter pylori in the treatment of peptic ulcer].
Topics: Gastric Mucosa; Helicobacter pylori; Histamine H2 Antagonists; Humans; Omeprazole; Recurrence; Stoma | 1995 |
Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized
Topics: Adult; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer | 1995 |
Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duode | 1995 |
Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease.
Topics: Adult; Amoxicillin; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter pylori; Human | 1995 |
Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Heli | 1995 |
Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence.
Topics: Adult; Aged; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Fo | 1995 |
Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers.
Topics: Adolescent; Adult; Aged; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer | 1995 |
Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 1995 |
[Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 1994 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Histological maturity of healed duodenal ulcer and ulcer recurrence after treatment with omeprazole or cimetidine.
Topics: Adolescent; Adult; Aged; Cimetidine; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omeprazole; | 1994 |
Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. A 12-month follow-up.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Chi-Square Distribution; Confidence Intervals; Drug Ther | 1995 |
Causal role of Helicobacter pylori in peptic ulcer relapse.
Topics: Aged; Amoxicillin; Bismuth; Chi-Square Distribution; Drug Therapy, Combination; Gastric Mucosa; Heli | 1994 |
Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Esophagitis, Peptic; Female; Gastric Mucosa; Gastrins; | 1994 |
A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group.
Topics: Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Dilatation; Double-Blind Method; Esophageal | 1994 |
Bismuth-free triple therapy for eradicating Helicobacter pylori and reducing the gastric ulcer recurrence rate.
Topics: Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Fatty Alcohols; Female; Gastr | 1994 |
Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; | 1994 |
Omeprazole versus famotidine in the healing and relapse of duodenal ulcer.
Topics: Absenteeism; Adult; Analgesics; Antacids; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; H | 1993 |
One-year follow-up of duodenal ulcers after 1-wk triple therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studi | 1994 |
Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin.
Topics: Adolescent; Adult; Aged; Amoxicillin; Drug Administration Schedule; Drug Therapy, Combination; Duode | 1993 |
Orally administered omeprazole versus injection therapy in the prevention of rebleeding from peptic ulcer with visible vessel. A multicenter randomized study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Duodenal Ulcer; Epi | 1993 |
Prevention of duodenal ulcer recurrence with penicillin. A double-blind, placebo-controlled trial.
Topics: Double-Blind Method; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; M | 1993 |
Effect of Helicobacter pylori eradication on the healing and recurrence of peptic ulcer: combination therapy with low-dose omeprazole and clarithromycin.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; | 1995 |
Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Confidence Intervals; Dose-Response Relationship, | 1995 |
Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer.
Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gastric Acidity Determination; Humans; Hydrogen-Io | 1995 |
Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Double-Blind Method; Esopha | 1996 |
Intravenous omeprazole prevents rebleeding in peptic ulcer patients with a non-bleeding visible vessel: a preliminary report of a randomized controlled study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenum; Female; Follow-Up Studies; Humans; Infu | 1996 |
Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Com | 1996 |
Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Chile; Drug Therapy, Combination; | 1996 |
Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Drug Therapy, Co | 1996 |
Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1996 |
Cure of gastric ulcer disease after cure of Helicobacter pylori infection--German Gastric Ulcer Study.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biopsy; Bismuth; Drug Administration Schedule; Drug The | 1996 |
A trial of lansoprazole in refractory gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Anti-Ulcer Agents; Drug Resistanc | 1996 |
Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Enzy | 1996 |
Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dilatation; Double-Blind Method; Drug Ad | 1996 |
Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Duod | 1996 |
Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Gastroscopy; Helic | 1996 |
Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Heli | 1996 |
Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.
Topics: Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Drug Therapy, Co | 1996 |
Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Ulcer | 1996 |
Omeprazole in the treatment of patients with complicated gastro-oesophageal reflux disease.
Topics: Antacids; Anti-Ulcer Agents; Dilatation; Esophageal Stenosis; Esophagitis, Peptic; Female; Follow-Up | 1996 |
Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-U | 1996 |
Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Female; Follow-Up Studies; Helicobacter | 1997 |
Lansoprazole and amoxycillin: observations on the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Double-Bli | 1997 |
A comparison of omeprazole and placebo for bleeding peptic ulcer.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy, Gastrointestinal; Fe | 1997 |
A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, | 1997 |
Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 1997 |
Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi-centre double-blind study.
Topics: Anti-Ulcer Agents; Double-Blind Method; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Omep | 1997 |
Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease.
Topics: Aged; Anti-Ulcer Agents; Antidiarrheals; Cross-Over Studies; Double-Blind Method; Endoscopy, Digesti | 1997 |
Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice.
Topics: Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Family Practice; Female; Gastr | 1997 |
Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug The | 1996 |
Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Female; Helicobacte | 1997 |
A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Blood Transfusion; Cimetidine; Female | 1998 |
Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Biopsy; Double-Blind Method | 1997 |
Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bed Rest; Dose- | 1997 |
Prevention of gastric ulcer recurrence with tetraprenylacetone.
Topics: Adult; Aged; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Female; Gastric Mucosa; Helic | 1998 |
Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-B | 1998 |
Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Dose-Response Relationship | 1997 |
Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment.
Topics: Adult; Aged; Biopsy; Cimetidine; Drug Administration Schedule; Drug Resistance; Enzyme Inhibitors; E | 1997 |
Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Cell Count; Double-Blind Method; | 1998 |
Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Helicobacter pylori eradication in the healing and recurrence of benign gastric ulcer: a two-year, double-blind, placebo controlled study.
Topics: Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter | 1997 |
Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study.
Topics: Adult; Amoxicillin; Antacids; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; | 1998 |
Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis; G | 1997 |
Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Cl | 1998 |
Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo.
Topics: Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Endoscopy, Gastrointestinal; E | 1998 |
Omeprazole in the treatment of ulcers induced by NSAIDs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agen | 1998 |
Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Chronic Disease; Duodenal Ulcer; | 1998 |
Histological esophagitis: clinical and histological response to omeprazole in children.
Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Esophagitis; Esophagoscopy; Female; Gastrins | 1999 |
[Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Follow-Up Studies; Helico | 1999 |
[A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Admini | 1999 |
[Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 1999 |
The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Cost-Benefit Analysis; Decision Trees; Duodenal Ulcer; Hel | 1995 |
Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
Topics: Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Esophagitis, Peptic; Female; G | 1999 |
"Reappearance" of Helicobacter pylori after eradication: implications on duodenal ulcer recurrence: a prospective 6 year study.
Topics: Adolescent; Adult; Aged; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicob | 1999 |
The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Female; Helicobacter Infections; Helicobacter p | 1999 |
Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Me | 1999 |
Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Drug R | 1999 |
Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study.
Topics: Absenteeism; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Animals; Anti-Ulcer Agents | 1999 |
Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1999 |
Use of omeprazole in the management of giant duodenal ulcer: results of a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Biopsy; Duodenal Ulcer; Female; Gastroscopy; Heli | 1999 |
Assessment of decisions in the treatment of Helicobacter pylori-related duodenal ulcer: a cost-effectiveness study.
Topics: Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; China; Cimetidine; Cost-Be | 1999 |
[Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication].
Topics: Adult; Amoxicillin; Bismuth; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Duodenal Ul | 1999 |
Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; D | 2000 |
Efficacy of bismuth-based triple therapy in children with abdominal pain and Helicobacter pylori gastritis.
Topics: Abdominal Pain; Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool | 2000 |
Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Respon | 2000 |
Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin; | 2000 |
Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group.
Topics: Adolescent; Adult; Aged; Algorithms; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Foll | 2000 |
High dose proton pump inhibitor response as an initial strategy for a clinical diagnosis of gastro-oesophageal reflux disease (GERD). Swedish multi-centre group in primary health care.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Gastroesophageal Reflux; Humans; Mi | 2000 |
Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Female; Histamine | 2000 |
Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2000 |
[Peptic ulcer hemorrhage: i.v. antacid prevents recurrence].
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Omep | 2000 |
Recurrent ulcer bleeding: is intravenous omeprazole the solution?
Topics: Anti-Ulcer Agents; Double-Blind Method; Humans; Omeprazole; Peptic Ulcer Hemorrhage; Recurrence | 2001 |
Eradication of Helicobacter pylori infection in patients with duodenal ulcer and non-ulcer dyspepsia and analysis of one-year reinfection rates.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duoden | 2001 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarit | 2001 |
Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Analysis of Variance; Anti-Bacterial Agents; A | 2001 |
Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2001 |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacter | 2001 |
Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers.
Topics: Aged; Double-Blind Method; Endoscopy, Digestive System; Epinephrine; Female; Humans; Hyperthermia, I | 2001 |
Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antifibrinolytic Agents; Blood Transfusi | 2001 |
Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer.
Topics: Anti-Ulcer Agents; Chi-Square Distribution; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Ga | 2001 |
Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease.
Topics: Adult; Aged; Clarithromycin; Double-Blind Method; Female; Gastroesophageal Reflux; Helicobacter Infe | 2001 |
[Piracetam in combined pathogenetic therapy of recurrent duodenal ulcer].
Topics: Adolescent; Adult; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulc | 2002 |
Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 2002 |
Recurrent bleeding from peptic ulcer associated with adherent clot: a randomized study comparing endoscopic treatment with medical therapy.
Topics: Blood Coagulation; Endoscopy; Epinephrine; Female; Humans; Injections; Male; Middle Aged; Omeprazole | 2002 |
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2002 |
Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter pylori; Humans; Metronidazole; Omep | 1992 |
Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug.
Topics: Anti-Ulcer Agents; Cisapride; Double-Blind Method; Esophagitis, Peptic; Female; Humans; Male; Middle | 1992 |
Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duoden | 1992 |
Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: a double-blind, multicenter, 6-month study. The Omeprazole Duodenal Ulcer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Female; Humans; Male; Middle Ag | 1992 |
Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine.
Topics: Adult; Aged; Biopsy; Chi-Square Distribution; Esophagitis, Peptic; Esophagoscopy; Gastric Mucosa; Ga | 1991 |
Acid secretory responses and parietal cell sensitivity following duodenal ulcer healing with omeprazole, sucralfate, and Maalox.
Topics: Adult; Aged; Aluminum Hydroxide; Antacids; Drug Combinations; Duodenal Ulcer; Endoscopy, Gastrointes | 1991 |
High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study.
Topics: Adult; Double-Blind Method; Esophagitis; Esophagoscopy; Famotidine; Female; Humans; Male; Middle Age | 1991 |
Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Female; Gastrins; H | 1991 |
Two and four weeks' treatment for duodenal ulcer. Symptom relief and clinical remission comparing omeprazole and ranitidine. Scandinavian Clinics for United Research.
Topics: Absenteeism; Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antacids; Drug Administrati | 1991 |
Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine.
Topics: Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Gastric Acidity Determination; Gastric Muco | 1990 |
Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: a randomized double-blind study with weekly endoscopic assessment.
Topics: Adult; Double-Blind Method; Duodenal Ulcer; Duodenoscopy; Female; Humans; Male; Omeprazole; Ranitidi | 1989 |
Use of omeprazole in the management of reflux oesophagitis resistant to H2-receptor antagonists.
Topics: Esophagitis, Peptic; Gastric Acid; Histamine H2 Antagonists; Humans; Multicenter Studies as Topic; O | 1989 |
Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer.
Topics: Adult; Aged; Analysis of Variance; Clinical Trials as Topic; Double-Blind Method; Female; Follow-Up | 1989 |
Relapse of gastric ulcers after healing with omeprazole and cimetidine. A double-blind follow-up study. Danish Omeprazole Study Group.
Topics: Adolescent; Adult; Aged; Cimetidine; Clinical Trials as Topic; Double-Blind Method; Female; Follow-U | 1989 |
Duodenal ulcer treated with omeprazole: healing and relapse rates. Does treatment duration influence subsequent remission?
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Duodenal Ulcer; Female; Humans; Male; Middle Aged | 1989 |
Healing and relapse of severe peptic esophagitis after treatment with omeprazole.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Esop | 1988 |
Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial.
Topics: Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cimetidine; Clinical Trials as Topic; Double-Blind M | 1985 |
165 other studies available for omeprazole and Recrudescence
| Article | Year |
|---|---|
Effects of Omeprazole on Recurrent Clostridioides difficile Infection Caused by ST81 Strains and Their Potential Mechanisms.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fluoroquinolones; Humans; O | 2023 |
It's What's Up Front That Counts-Part Two: Esophageal Crohn's Disease Complicated by Recurrent Upper Gastrointestinal Bleeding.
Topics: Adalimumab; Anti-Bacterial Agents; Anti-Inflammatory Agents; Budesonide; Colonoscopy; Colostomy; Con | 2019 |
Retrospective analysis of the use of quadruple therapy with bismuth (Pylera
Topics: Adult; Aged; Breath Tests; Cross-Sectional Studies; Drug Evaluation; Drug Therapy, Combination; Fema | 2018 |
Prevalence of Helicobacter pylori and its recurrence after successful eradication in a developing nation (Morocco).
Topics: Adult; Amoxicillin; Anti-Infective Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Developing | 2013 |
[Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Drug Interactio | 2014 |
The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Endoscopy; Eosinophilic Esophagitis; Fema | 2016 |
French comment on article: High-dose omeprazole infusion compared with scheduled second-look endoscopy for prevention of peptic ulcer rebleeding: a randomized controlled trial.
Topics: Anti-Ulcer Agents; Endoscopy; Humans; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Recurrence; | 2016 |
Effect of baseline characteristics on response to proton pump inhibitors in patients with peptic ulcer bleeding.
Topics: Adult; Aged; Aged, 80 and over; Asian People; China; Esomeprazole; Europe; Female; Health Status; He | 2017 |
[Antihelicobacteric therapy for the patients with recurrent complicated postoperative gastroduodenal ulcer: indications, principles of conduction, efficacy].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; | 2009 |
Management of acute peptic ulcers: how ethnicity, different proton pump inhibitors and mechanism of delivery alter the equation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Asian People; Drug Administration Sch | 2009 |
Combined treatment of achalasia - botulinum toxin injection followed by pneumatic dilatation: long-term results.
Topics: Adult; Aged; Aged, 80 and over; Botulinum Toxins, Type A; Catheterization; Cohort Studies; Combined | 2010 |
Recurrent peptic ulcer disease in a pediatric patient with type 1 neurofibromatosis and primary ciliary dyskinesia.
Topics: Adult; Age Factors; Anti-Ulcer Agents; Child, Preschool; Ciliary Motility Disorders; Female; Follow- | 2009 |
Recurrent cytomegalovirus infection in ileal pouch-anal anastomosis for ulcerative colitis.
Topics: Ciprofloxacin; Colitis, Ulcerative; Colonic Pouches; Cytomegalovirus Infections; Dietary Supplements | 2010 |
Stool transplantation for older patients with Clostridium difficile infection.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Dr | 2009 |
[Prevalence of rebleeding from peptic ulcer in patients treated with proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Costs; Female; Health Resources; Hospital Costs; | 2010 |
Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Drug Administration Schedul | 2011 |
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clop | 2011 |
[Characteristics of duodenogastric reflux in duodenal ulcer patients and its dynamics after Helicobacter pylori eradication].
Topics: Adult; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenogastric Reflux | 2011 |
Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cohort Studies; Duodenal Ul | 2002 |
[Concerning the discussion article by I. A. Morozov "Choice of the gastroenterologist"].
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Gastric Acid; Gastric Acidity Determination; Gastric Juice; Gastr | 2002 |
Pantoprazole-induced recurrent anaphylactic shock.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Enzy | 2002 |
Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium.
Topics: Adult; Aged; Aged, 80 and over; Barrett Esophagus; Bile Reflux; Esophagus; Follow-Up Studies; Humans | 2002 |
Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy.
Topics: Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Cohort Studies; Female; Gastroesophageal Reflux; | 2002 |
Facial swelling and eosinophilia in a 44-year-old woman.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Angioedema; Cefuroxime; Cetirizine; Diagnosis, Diffe | 2002 |
[Is gastric and duodenal ulcer drug-treatable or surgical disease?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Humans; Lansoprazole; Om | 1997 |
Efficacy of a paste formulation of omeprazole for the treatment of naturally occurring gastric ulcers in training standardbred racehorses in Canada.
Topics: Administration, Oral; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Female; Gastrosc | 2003 |
Treatment of patients at high risk for recurrent bleeding from a peptic ulcer.
Topics: Anti-Ulcer Agents; Combined Modality Therapy; Endoscopy, Gastrointestinal; Gastrointestinal Hemorrha | 2003 |
Summaries for patients. Combination treatment for peptic ulcers at high risk for recurrent bleeding.
Topics: Anti-Ulcer Agents; Combined Modality Therapy; Endoscopy, Gastrointestinal; Female; Gastrointestinal | 2003 |
Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy.
Topics: Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Biopsy; Breath Tests; Clarithromycin; Cohort Stud | 2003 |
[Heartburn without esophagitis. Symptoms more important than the finding?].
Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul | 2003 |
Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2003 |
Outcome of laparoscopic Nissen-Rossetti fundoplication in children with gastroesophageal reflux disease and supraesophageal symptoms.
Topics: Adolescent; Anti-Ulcer Agents; Asthma; Child; Child, Preschool; Combined Modality Therapy; Domperido | 2004 |
Adverse events following discharge from the hospital.
Topics: Anti-Ulcer Agents; Gastroesophageal Reflux; Health Maintenance Organizations; Humans; Male; Middle A | 2004 |
Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Anticonvulsants; Consumer Product Safety; Drug Labeling; Femal | 2004 |
Management options for patients with ulcer hemorrhage.
Topics: Anti-Ulcer Agents; Combined Modality Therapy; Endoscopy, Gastrointestinal; Gastrointestinal Hemorrha | 2004 |
Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis.
Topics: Acinonyx; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; | 2004 |
Monocyte chemotactic protein-1 regulates leukocyte recruitment during gastric ulcer recurrence induced by tumor necrosis factor-alpha.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulce | 2004 |
Recurrent anaphylaxis linked to pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylas | 2004 |
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Humans; Lansoprazol | 2005 |
Helicobacter pylori and recurrent pain abdomen.
Topics: Abdominal Pain; Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Endos | 2005 |
Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Asthmatic Agents; Anti-Ulcer Agents; Asthma; Child; Ch | 2006 |
Helicobacter pylori: factors affecting eradication and recurrence.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Omeprazole maintenance therapy prevents recurrent ulcer bleeding after surgery for duodenal ulcer.
Topics: Aged; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Juice; Humans; Hydrogen-Ion Concentration; Male; Mi | 2006 |
Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients.
Topics: Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; | 2006 |
[Long term results of treatment by simple surgical closure of perforated gastroduodenal ulcer followed by eradication of Helicobacter pylori].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromyc | 2006 |
Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Administration, Oral; Aged; Aged, 80 and ove | 2006 |
Pre-endoscopic PPI therapy reduces recurrent adverse outcomes in acute non-variceal upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Administration, Oral; Aged; Aged, 80 and ove | 2007 |
Continuous infusion of high-dose omeprazole is more effective than standard-dose omeprazole in patients with high-risk peptic ulcer bleeding: a retrospective study.
Topics: Aged; Anti-Ulcer Agents; Blood Transfusion; Dose-Response Relationship, Drug; Endoscopy, Gastrointes | 2007 |
[The 10-minute-consultation: chronic singultus].
Topics: Aged; Amines; Anti-Ulcer Agents; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Diag | 2007 |
Helicobacter pylori recurrence and infection rate in Israeli adults.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Breath Tests; Chi-Square Distribution; | 2008 |
Prospective Acid Reflux Study of Iran (PARSI): methodology and study design.
Topics: Biopsy; Comorbidity; Drug Administration Schedule; Esophagogastric Junction; Esophagus; Feasibility | 2007 |
[A case report of prosthetic valve replacement for malfunction of the Hancock valve in mitral position associated with recurrent peptic ulcer and renal dysfunction].
Topics: Female; Heart Valve Prosthesis; Humans; Kidney Diseases; Middle Aged; Mitral Valve; Omeprazole; Pept | 1995 |
[Do proton pump inhibitors after endoscopic control of acute ulcer hemorrhage have an advantage over H2 receptor antagonists?].
Topics: Adult; Aged; Anti-Ulcer Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Ad | 1995 |
[Long-term therapy with omeprazole: when will it finally be approved?].
Topics: Anti-Ulcer Agents; Drug Approval; Esophagitis, Peptic; Humans; Long-Term Care; Omeprazole; Recurrenc | 1995 |
Schönlein-Henoch purpura associated with gastric Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Biopsy; Breath Tests; Chronic Disease; Drug Therapy, Combinat | 1995 |
[Peptic ulcer hemorrhage and acid suppression. More is better?].
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Gastric Acidity Determination; Hemostasi | 1995 |
Healing and relapse rates of duodenal ulcer with omeprazole vs ranitidine.
Topics: Adolescent; Adult; Aged; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omeprazole; Ranitidine; | 1995 |
Repeat laser therapy of recurrent Barrett's epithelium: success with anacidity.
Topics: Barrett Esophagus; Combined Modality Therapy; Esophagus; Follow-Up Studies; Gastric Acidity Determin | 1995 |
[Peptic ulcer: changing indications for gastric resection during the last 15 years].
Topics: Histamine H2 Antagonists; Humans; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Peptic Ulcer Pe | 1994 |
Helicobacter pylori eradication in the African setting, with special reference to reinfection and duodenal ulcer recurrence.
Topics: Adult; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazol | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Helicobacte | 1995 |
Recurrent acute interstitial nephritis on rechallenge with omeprazole.
Topics: Acute Disease; Aged; Humans; Male; Nephritis, Interstitial; Omeprazole; Recurrence | 1994 |
Peptic ulcer disease in adolescence: changing concepts in the age of Helicobacter pylori.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Helicobacter Infections; Helicobac | 1994 |
[Maintenance therapy with antiulcer drugs: review of 71 cases].
Topics: Aluminum Hydroxide; Antacids; Anti-Ulcer Agents; Carbonates; Cross-Over Studies; Duodenal Ulcer; Fam | 1995 |
Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combinatio | 1994 |
Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cohort Studies; Drug Therapy, Combination; Fe | 1994 |
Prevention of duodenal ulcer relapse by long-term treatment with omeprazole.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Duodenal Ulcer; Humans; Middle Aged; Multicenter Studies | 1994 |
Helicobacter pylori: a fickle germ.
Topics: Aerobiosis; Culture Media; False Negative Reactions; Gastritis; Helicobacter Infections; Helicobacte | 1994 |
Endoscopic ultrasonographic (EUS) evaluation of the quality of gastric ulcer healing.
Topics: Gastroscopy; Histamine H2 Antagonists; Humans; Omeprazole; Recurrence; Stomach; Stomach Ulcer; Time | 1993 |
Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Fem | 1994 |
[Hemostasis and treatment of stress hemorrhage in the upper gastrointestinal tract of trauma patients].
Topics: Cimetidine; Combined Modality Therapy; Croatia; Endoscopy, Gastrointestinal; Gastrectomy; Humans; Mi | 1993 |
[High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison].
Topics: Aged; Aged, 80 and over; Aluminum Hydroxide; Antacids; Dose-Response Relationship, Drug; Drug Admini | 1994 |
Assessing the cost-effectiveness of medical treatments in acid-related diseases. The Markov chain approach applied to a comparison between intermittent and maintenance treatment of reflux esophagitis.
Topics: Cost of Illness; Cost-Benefit Analysis; Decision Support Techniques; Esophagitis, Peptic; Humans; Ma | 1993 |
[Study on omeprazole 20 mg twice weekly in prevention of duodenal ulcer relapse].
Topics: Adolescent; Adult; Aged; Cimetidine; Drug Administration Schedule; Duodenal Ulcer; Female; Humans; M | 1993 |
The relationship between endoscopic findings of gastric ulcer scar and ulcer relapse.
Topics: Adult; Aged; Aged, 80 and over; Famotidine; Female; Gastric Mucosa; Gastroscopy; Humans; Male; Middl | 1993 |
[Inhibitors of proton pump, a new target: the visible vessel].
Topics: Combined Modality Therapy; Humans; Omeprazole; Peptic Ulcer Hemorrhage; Proton Pumps; Ranitidine; Re | 1993 |
[Evaluation of the cost of maintenance therapy (6 months) with 150 mg ranitidine vs 20 mg omeprazole vs 20 mg omeprazole every other day in duodenal ulcer].
Topics: Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Drug Administration Schedule; Duodenal Ulcer; | 1993 |
[Omeprazole prevention of the recurrence of peptic ulcer: the efficacy of treatment with 20 mg on alternate days].
Topics: Adult; Aged; Aged, 80 and over; Drug Evaluation; Female; Gastrins; Humans; Male; Middle Aged; Omepra | 1993 |
Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benef | 1996 |
Should omeprazole be used for the treatment and prevention of duodenal ulcer as a monotherapeutic agent?
Topics: Anti-Ulcer Agents; Chronic Disease; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Hu | 1996 |
Peptic esophageal stricture: is surgery still necessary?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cimetidine; Combined Modality Therapy | 1996 |
Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Cost-Benefit Analysis; Costs and Cost Analysis; D | 1996 |
Cost effectiveness of medical versus surgical treatment in patients with severe or refractory gastroesophageal reflux disease in the Netherlands.
Topics: Anti-Ulcer Agents; Cost-Benefit Analysis; Fundoplication; Gastroesophageal Reflux; Health Care Costs | 1996 |
Eradication of Helicobacter pylori followed by reinfection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Blot | 1996 |
Helicobacter pylori reinfection is rare in peptic ulcer patients cured by antimicrobial therapy.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-U | 1996 |
Previous use of non-steroidal anti-inflammatory drugs and anticoagulants: the influence on clinical outcome of bleeding gastroduodenal ulcers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agen | 1997 |
Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Inflammatory Agents, Non-Ste | 1997 |
Evaluation of the dyspeptic patient: a cost-utility study.
Topics: Adult; Ambulatory Care; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, | 1997 |
Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cost-Benefit Analysis; Esophagitis, Pept | 1997 |
Duodenal stenosis may not regress after eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Ulcer Agents; Constriction, Pathologic; Drug Therapy, Combination; Duodenal Ulcer; | 1997 |
Development of duodenal ulcer concomitant with successful Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobact | 1997 |
Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy.
Topics: Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Anti-Ulcer Agents; Child; Child, Preschool; Depres | 1997 |
Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study.
Topics: Anti-Ulcer Agents; Cough; Deglutition Disorders; Female; Follow-Up Studies; Gastroesophageal Reflux; | 1997 |
Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Case-Control Studies; Cost-Benefit Analy | 1997 |
Recurrent severe acute hepatitis and omeprazole.
Topics: Acute Disease; Adult; Anti-Ulcer Agents; Chemical and Drug Induced Liver Injury; Humans; Male; Omepr | 1997 |
[Prevention of recurrent erosive reflux esophagitis].
Topics: Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophagitis, Pept | 1997 |
Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Carcinoid Tumor; Famotidine; Hist | 1998 |
PPIs vs H2RAs for erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Cost-Benefit Analysis; Enzyme Inhibitors; Es | 1998 |
[Helicobacter pylori infection and recurrent abdominal pain in children. A proved relationship?].
Topics: Abdominal Pain; Adolescent; Adult; Age Factors; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-U | 1998 |
Natural history of severe duodenal ulcer disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; Female; | 1998 |
Treatment of gastric MALT lymphoma by Helicobacter pylori eradication: a study controlled by endoscopic ultrasonography.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Endosonography; Fe | 1998 |
Therapies for ulcers associated with nonsteroidal antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Humans; Misoprostol; Omeprazole; Peptic | 1998 |
[Is dental plaque a normal Helicobacter pylori reservoir?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Benzimidazoles; Clari | 1998 |
Pyrexia, anaemia and acute renal failure secondary to omeprazole.
Topics: Acute Kidney Injury; Aged; Anemia; Anti-Inflammatory Agents; Anti-Ulcer Agents; Blood Sedimentation; | 1998 |
Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results.
Topics: Adult; Antacids; Anti-Ulcer Agents; Argon; Barrett Esophagus; Combined Modality Therapy; Electrocoag | 1998 |
Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
[Triple treatment for the eradication of Helicobacter pylori infection].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infec | 1998 |
Low-dose omeprazole for erosive esophagitis.
Topics: Adult; Anti-Ulcer Agents; Double-Blind Method; Esophagitis, Peptic; Humans; Omeprazole; Randomized C | 1999 |
Cost-effectiveness analysis of different strategies for treating duodenal ulcer. Helicobacter pylori eradication versus antisecretory treatment.
Topics: Anti-Ulcer Agents; Cost-Benefit Analysis; Duodenal Ulcer; Helicobacter pylori; Humans; Markov Chains | 1997 |
Omeprazole and bleeding peptic ulcer, or "how case-control studies can tell you what you suspected all along".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Case-Control Studies; Confounding Factor | 1999 |
Will Helicobacter pylori affect short-term rebleeding rate in peptic ulcer bleeding patients after successful endoscopic therapy?
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Blood Transfusion; Confidence Intervals; Duodenal | 1999 |
Helicobacter pylori and omeprazole therapy in GERD.
Topics: Enzyme Inhibitors; Esophagitis, Peptic; Gastroesophageal Reflux; Helicobacter Infections; Helicobact | 1999 |
Duodenal ulcer relapse is not always associated with recurrence of H. pylori infection: a prospective three-year follow-up study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; | 1999 |
Relapse of duodenal ulcers after successful eradication of Helicobacter pylori in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1999 |
The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chile; Developing Countries; Drug Therapy, | 2000 |
[Congress of the American College of Surgeons (ACS). San Francisco, 10-15 October 1999].
Topics: Anti-Ulcer Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholang | 1999 |
Reflux esophagitis: healed! Now what?
Topics: Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esophagitis, Peptic; Follow-Up Studies; Forecasti | 2000 |
Selection of patients for successful maintenance treatment of esophagitis with low-dose omeprazole: use of 24-hour gastric pH monitoring.
Topics: Adult; Aged; Confidence Intervals; Enzyme Inhibitors; Esophagitis, Peptic; Esophagoscopy; Female; Fo | 2000 |
Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy.
Topics: Adult; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Resistance; Enzyme | 2000 |
Clinical evolution of laryngeal granulomas: treatment and prognosis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Antiemetics; Botulinum Toxins, Type A; Combined Modality | 1999 |
Should we eradicate Helicobacter pylori in patients with recurrent gastro-oesophageal reflux disease?
Topics: Esophagitis; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Human | 2000 |
[Effects of Helicobacter pylori eradication on the recurrence of gastric ulcer during a 12-month follow up].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Da | 2000 |
Helicobacter pylori infection in recurrent abdominal pain.
Topics: Abdominal Pain; Adolescent; Amoxicillin; Anti-Ulcer Agents; Breath Tests; Child; Child, Preschool; C | 2000 |
Effect of cure rate on reinfection with H. pylori: a three-year follow-up study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Follow-Up Studie | 2000 |
Effect of amoxicillin, clarithromycin, and rabeprazole, a new proton pump inhibitor, in eradication therapy for relapsing peptic ulcer diseases with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2000 |
The use of AP-PCR and flaA-RFLP typing to investigate treatment failure in Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Clar | 2000 |
Recurrence of Helicobacter pylori infection and duodenal ulcer relapse, following successful eradication in an urban east Asian population.
Topics: Adolescent; Adult; Age Distribution; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Ch | 2000 |
Antireflux surgery in children suffering from reflux-associated respiratory disease?
Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Female; Gastroesophageal Reflux; Humans; Inf | 2001 |
Omeprazole maintenance therapy for gastroesophageal reflux disease after failure of fundoplication.
Topics: Child; Child, Preschool; Enzyme Inhibitors; Esophagitis, Peptic; Female; Follow-Up Studies; Fundopli | 2001 |
Acid regulates inflammatory response in a rat model of induction of gastric ulcer recurrence by interleukin 1beta.
Topics: Analysis of Variance; Animals; Anti-Ulcer Agents; Enzyme-Linked Immunosorbent Assay; Gastric Acid; H | 2001 |
Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa.
Topics: Angiodysplasia; Blood Transfusion; Combined Modality Therapy; Deamino Arginine Vasopressin; Estrogen | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
The effectiveness of one-week triple eradication therapy for perforated duodenal ulcer patients treated with simple closure.
Topics: Adult; Amoxicillin; Clarithromycin; Combined Modality Therapy; Dose-Response Relationship, Drug; Dru | 2001 |
The relationship between gastric-oral Helicobacter pylori and oral hygiene in patients with vitamin B12-deficiency anemia.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anemia, Pernicious; Anti-Bacterial Agents; Anti-Ulcer A | 2001 |
Short-term changes in Helicobacter pylori gastritis and bulbitis during and after 2 weeks of treatment with omeprazole and amoxicillin in duodenal ulcer patients.
Topics: Adult; Aged; Amoxicillin; Biopsy; Drug Therapy, Combination; Duodenal Ulcer; Duodenitis; Endoscopy, | 2001 |
[Current principles of the use of laparoscopic surgery in gastroduodenal ulcer].
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duode | 2001 |
Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antibodies, Bacterial; Antigens, Bacterial; Br | 2001 |
Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bangladesh; Body Mass Index; Breath Tests; Carbon Isotopes; D | 2001 |
Diagnostic methods for detecting forms and strains of Helicobacter pylori and evaluation of its eradication.
Topics: Adolescent; Adult; Aged; Antibodies, Bacterial; Bismuth; DNA Fingerprinting; Duodenal Ulcer; Female; | 2001 |
The novel use of an intravenous proton pump inhibitor in a patient with short bowel syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastrointestinal Hemorrh | 2002 |
[Long-term prophylaxis with omeprazol is superior to eradication therapy in H. pylori-positive NSAIDs taking patients].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Helicobacter Inf | 2002 |
Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as Topic; Helicobacter I | 2002 |
Influence of Helicobacter pylori infection on healing and relapse of acetic acid ulcers in Mongolian gerbils.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cyclooxygenase Inh | 2002 |
Prevalence of H. pylori-infection in family members of H. pylori positive and its influence on the reinfection rate after successful eradication therapy: a two-year follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breath Tests; Child; Child, Preschool; Clarithromycin; D | 2002 |
Pantoprazole-induced recurrent anaphylactic shock.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anaphylaxis; Benzimidazoles; Esophagitis, Peptic; Hu | 2002 |
[Recurrent peptic ulcer after gastric surgery].
Topics: Adenosine Triphosphatases; Adult; Aged; Female; Gastrectomy; Gastric Acid; Gastrins; H(+)-K(+)-Excha | 1992 |
[Proton pump inhibitor for maintenance therapy of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Endoscopy, Gastrointestinal; H(+ | 1992 |
[Changes in the treatment of peptic ulcer following the development of proton pump inhibitors].
Topics: Adenosine Triphosphatases; Animals; Depression, Chemical; Gastric Acid; H(+)-K(+)-Exchanging ATPase; | 1992 |
Medical therapy of patients with reflux oesophagitis poorly responsive to H2-receptor antagonist therapy.
Topics: Administration, Oral; Chronic Disease; Esophagitis, Peptic; Follow-Up Studies; Gastric Acidity Deter | 1992 |
[Relapse of peptic ulcer after quick healing induced by proton pump inhibitors].
Topics: Adenosine Triphosphatases; Animals; Endoscopy, Gastrointestinal; Gastric Mucosa; H(+)-K(+)-Exchangin | 1992 |
Bleeding from staple line erosion after esophageal transection: effect of omeprazole.
Topics: Adult; Aged; Depression, Chemical; Drug Evaluation; Esophageal and Gastric Varices; Esophagus; Femal | 1992 |
Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis.
Topics: Adult; Aged; Body Weight; Drug Administration Schedule; Drug Resistance; Esophagitis, Peptic; Esopha | 1991 |
Treatment of high-output gastric fistulas with omeprazole.
Topics: Gastric Fistula; Humans; Male; Middle Aged; Omeprazole; Recurrence | 1991 |
[Ciprofloxacin-omeprazole combination therapy for eradication of Helicobacter pylori].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Campylobacter Infections; Ciprofloxacin; Drug | 1991 |
Acid reduction and recurrent enteritis.
Topics: Adult; Gastroenteritis; Humans; Male; Omeprazole; Recurrence; Salmonella Infections | 1990 |
Omeprazole in H2 receptor antagonist-resistant reflux esophagitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Resistance; Esophagitis, Peptic; Female; Histamine | 1990 |
Temporary cessation of long-term maintenance treatment with omeprazole in patients with H2-receptor-antagonist-resistant reflux oesophagitis. Effects on symptoms, endoscopy, serum gastrin, and gastric acid output.
Topics: Adult; Aged; Esophagitis, Peptic; Esophagoscopy; Fasting; Female; Gastric Acid; Gastrins; Histamine | 1990 |
[Bullous pemphigoid secondary corticoresistant. Inhibitory role of omeprazole on corticosteroid metabolism?].
Topics: Adult; Drug Interactions; Drug Resistance; Female; Humans; Microsomes, Liver; Omeprazole; Pemphigoid | 1991 |
[Possibility of prednisone-omeprazole interference in bullous pemphigoid].
Topics: Adult; Drug Interactions; Female; Humans; Omeprazole; Pemphigoid, Bullous; Prednisone; Recurrence; U | 1990 |
Elimination of Helicobacter pylori under treatment with omeprazole.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; | 1990 |
Duodenal ulcer resistant to usual omeprazole dose.
Topics: Drug Resistance; Duodenal Ulcer; Gastric Acid; Humans; Male; Middle Aged; Omeprazole; Recurrence | 1990 |
Managing recurrent oesophagitis.
Topics: Antacids; Esophagitis, Peptic; Female; Gastric Fundus; Histamine H2 Antagonists; Humans; Middle Aged | 1989 |
Resistant duodenal ulcer: when, why and what to do?
Topics: Aged; Anti-Ulcer Agents; Cimetidine; Duodenal Ulcer; Histamine H2 Antagonists; Humans; Male; Omepraz | 1988 |
Beneficial effect of omeprazole in a patient with severe bronchial asthma and gastro-oesophageal reflux.
Topics: Adult; Asthma; Domperidone; Gastroesophageal Reflux; Humans; Male; Omeprazole; Ranitidine; Recurrenc | 1988 |
Duodenal ulcer disease.
Topics: Anti-Ulcer Agents; Benzimidazoles; Campylobacter Infections; Cimetidine; Duodenal Ulcer; Duodenoscop | 1985 |